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ABSTRACT 
We recently developed novel AAV capsids for efficient and noninvasive gene transfer across the 
central and peripheral nervous systems. In this protocol, we describe how to produce and 
systemically administer AAV-PHP viruses to label and/or genetically manipulate cells in the 
mouse nervous system and organs including the heart. The procedure comprises three 
separate stages: AAV production, intravenous delivery, and evaluation of transgene expression. 
The protocol spans eight days, excluding the time required to assess gene expression, and can 
be readily adopted by laboratories with standard molecular and cell culture capabilities. We 
provide guidelines for experimental design and choosing the capsid, cargo, and viral dose 
appropriate for the experimental aims. The procedures outlined here are adaptable to diverse 
biomedical applications, from anatomical and functional mapping to gene expression, silencing, 
and editing. 
 
INTRODUCTION  
Recombinant adeno-associated viruses (AAVs) are commonly used vehicles for in vivo gene 
transfer and promising vectors for therapeutic applications1. However, AAVs that enable efficient 
and noninvasive gene delivery across defined cell populations are needed. Current gene 
delivery methods (e.g., intraparenchymal surgical injections) are invasive, and alternatives such 
as intravenous administration require high viral doses and still provide relatively inefficient 
transduction of target cells. We previously developed CREATE (Cre REcombination-based AAV 
Targeted Evolution) to engineer and screen for AAV capsids capable of more efficient gene 
transfer to specific cell types via the vasculature2,3. Compared to naturally occurring capsids, the 
novel AAV-PHP capsids exhibit markedly improved tropism for cells in the adult mouse central 
nervous system (CNS), peripheral nervous system (PNS), and visceral organs. In this protocol, 
we describe how to package genetic cargo into AAV-PHP capsids and intravenously administer 
AAVs for efficient and noninvasive gene delivery throughout the body (Fig. 1). 
We recently identified several new capsid variants with distinct tropisms2,3. AAV-PHP.B 
and the further evolved AAV-PHP.eB efficiently transduce neurons and glia throughout the CNS 
(Fig. 2); a second variant, AAV-PHP.S, displays improved tropism for neurons within the PNS 
(Fig. 3) and organs including the gut2 and heart (Fig. 4). Importantly, these capsids target cell 
populations that are normally difficult to access due to their location (e.g., sympathetic, nodose, 
dorsal root, and cardiac ganglia) (Fig. 3a-c and Fig. 4d) or broad distribution (e.g., throughout 
the brain or enteric nervous system) (Figs. 2 and 3d). Together with the capsid, the genetic 
cargo (or AAV genome) can be customized to control transgene expression (Fig. 5 and Table 
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1). The recombinant AAV (rAAV) genome contains the components required for gene 
expression including promoters, transgenes, protein trafficking signals, and recombinase-
dependent expression schemes. Hence, different capsid-cargo combinations create a versatile 
AAV toolbox for genetic manipulation of diverse cell populations in wild-type and transgenic 
animals. Here, we provide researchers, especially those new to working with AAVs or systemic 
delivery, with resources to utilize AAV-PHP viruses in their own research.  
 
Overview of the protocol  
We provide an instruction manual for users of AAV-PHP variants. The procedure includes three 
main stages (Fig. 1): AAV production (Steps 1-42), intravenous delivery (Steps 43-49), and 
evaluation of transgene expression (Step 50).  
The AAV production protocol is adapted from established methods. First, HEK293T cells 
are transfected with three plasmids4-6 (Steps 1-3) (Figs. 1 and 6): (1) pAAV, which contains the 
rAAV genome of interest (Fig. 5 and Table 1); (2) AAV-PHP Rep-Cap, which encodes the viral 
replication and capsid proteins; and (3) pHelper, which encodes adenoviral proteins necessary 
for replication. Using this triple transfection approach, the rAAV genome is packaged into an 
AAV-PHP capsid in HEK293T cells. AAV-PHP viruses are then harvested7 (Steps 4-14), 
purified8,9 (Steps 15-31), and titered10 (Steps 32-42) (Fig. 6). Purified viruses are intravenously 
delivered to mice via retro-orbital injection11 (Steps 43-49) and gene expression is later 
assessed using molecular, histological, or functional methods relevant to the experimental aims 
(Step 50). 
This protocol is optimized to produce AAVs at high titer (over 1013 vector genomes/ml) 
and with high transduction efficiency in vivo2,3. 
 
Experimental design 
Before proceeding with the protocol, a number of factors should be considered, namely the 
expertise and resources available in the lab; the capsid and rAAV genome to be used; the dose 
for intravenous administration; and the method(s) available for assessing transgene expression. 
Each of these topics is discussed below and intended to guide users in designing their 
experiments. 
 
Required expertise and resources. This protocol requires that scientists have basic molecular 
biology, cell culture, and animal work experience. Users should be approved to handle 
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laboratory animals, human cell lines, and AAVs. A background in molecular cloning is 
advantageous though not necessary if relying on available plasmids.  
 In addition to having the above expertise, labs must be equipped for the molecular and 
cell culture work relevant to the procedure; we suggest that users read through the entire 
materials and procedure sections beforehand to ensure that the required reagents and 
equipment are available and appropriate safety practices and institutional approvals are in 
place.  
 
Selecting an AAV-PHP capsid. We recommend choosing an AAV-PHP capsid based on its 
tropism and viral production efficiency. Capsid properties are listed in Supplementary Table 1; 
we include species, organs, and cell populations examined to date and note typical viral yields. 
We anticipate that most researchers will use AAV-PHP.eB (Addgene ID 103005) or AAV-PHP.S 
(Addgene ID 103006) in their experiments. AAV-PHP.eB and AAV-PHP.S produce viral yields 
similar to other high producing naturally occurring serotypes (e.g., AAV9) and enable efficient, 
noninvasive gene transfer to the CNS or PNS and visceral organs, respectively2 (Figs. 2-4).  
The earlier capsid variants, which provide broad CNS transduction, either produce 
suboptimal yields (AAV-PHP.A)3 or have since been further evolved for enhanced transduction 
efficiency in vivo (AAV-PHP.B (Addgene ID 103002))2. We therefore recommend using AAV-
PHP.eB for CNS applications, especially when targeting neurons. Note, however, that the 
chosen capsid will ultimately depend on the experimental circumstances; multiple factors 
including species12, age13, gender14, and health15 influence AAV tropism. Testing the AAV-PHP 
variants in a variety of experimental paradigms will continue to reveal the unique attributes of 
each capsid and identify those most suitable for different applications.  
 
Selecting a rAAV genome. Users must select a rAAV genome, contained in a pAAV plasmid, 
to package into the capsid (Figs. 1 and 5 and Table 1). In Table 1, we list pAAVs used here 
(Figs. 2-4) and in our previous work2,3; we direct users to Addgene’s plasmid repository for 
additional pAAVs developed for various applications. 
Depending on the experimental aims, users may elect to design their own genomes16 
and clone from existing pAAVs. When customizing plasmids, it is imperative that the rAAV 
genome, the sequence between and including the two inverted terminal repeats (ITRs), does 
not exceed 4.7-5 kb (Fig. 5); larger genomes will not be fully packaged into AAV capsids, 
resulting in truncated genomes and low titers. The ITRs are 145 base pair sequences that flank 
the expression cassette and are required for replication and encapsidation of the viral genome. 
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ITRs are typically derived from the AAV2 genome and must match the serotype of the rep gene 
contained in the AAV Rep-Cap plasmid; AAV-PHP Rep-Cap plasmids contain the AAV2 rep 
gene and are therefore capable of packaging genomes with AAV2 ITRs. Other genetic 
components (e.g., promoters, transgenes, localization signals, and recombination schemes) are 
interchangeable and can be customized for specific applications (Fig. 5).  
 
Dosage for intravenous administration. The optimal dose for intravenous administration to 
target cell populations must be determined empirically. We encourage users to consult Figures 
2-4 and related work for suggested AAV-PHP viral doses. The variants have been successfully 
employed for fluorescent labeling in adult mice2,3,17 (Figs. 2-4), neonatal mice17, and neonatal 
and adult rats18; they have also been administered for calcium imaging19,20 and optogenetic (Fig. 
4d), chemogenetic17, and therapeutic applications17,18.  
For applications using AAV-PHP.eB and AAV-PHP.S, we typically administer between 1 
x 1011 and 3 x 1012 vector genomes (vg) of virus to adult mice (≥6 weeks of age). However, 
dosage will vary depending on the target cell population, desired fraction of transduced cells, 
and expression level per cell. AAVs independently and stochastically transduce cells, typically 
resulting in multiple genome copies per cell2. Therefore, higher doses generally result in strong 
expression (i.e., high copy number) in a large fraction of cells, whereas lower doses result in 
weaker expression (i.e., low copy number) in a smaller fraction of cells. To achieve high 
expression in a sparse subset of cells, users can employ a two-component system in which 
transgene expression is dependent on co-transduction of an inducer (e.g., a vector expressing 
the tetracycline-controlled transactivator (tTA))2; inducers are injected at a lower dose (typically 
1 x 109 to 1 x 1011 vg) to limit the fraction of cells with transgene expression. Note that gene 
regulatory elements (e.g., enhancers and promoters) also influence gene expression levels. 
Therefore, users should assess transgene expression from a series of doses and at several 
time points after intravenous delivery to determine the optimal experimental conditions. 
 
Evaluation of transgene expression.  Following in vivo delivery, AAV transduction and 
transgene expression increase over the course of several weeks. While expression is evident 
within days after transduction, it does not reach a steady state level until at least 3-4 weeks. 
Therefore, we suggest waiting a minimum of 2 weeks before evaluating fluorescent 
labeling2,3,17,18 (Figs. 2-4) and at least 3-4 weeks before beginning optogenetic (Fig. 4d), 
chemogenetic17, and calcium imaging19,20 experiments. Note that like other AAVs, AAV-PHP 
variants are capable of providing long-term transgene expression. AAV-PHP.B-mediated 
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cortical expression of a genetically encoded calcium indicator, GCaMP6s, was reported to last 
at least 10 weeks post-injection without toxic side effects20 (i.e., nuclear filling21), and we have 
observed GFP expression throughout the brain more than one year after viral administration 
(see Supplementary Figure 4 in ref. 3). However, the time points suggested here are only meant 
to serve as guidelines; gene expression is contingent on multiple factors including the animal 
model, capsid, genome, and dose. 
The appropriate method(s) for evaluating transgene expression will vary among users. 
Fluorescent protein expression can be assessed in thin or thick (≥100 µm) tissue samples. The 
CLARITY-based methods PACT (passive CLARITY technique) and PARS (perfusion-assisted 
agent release in situ)22 render thick tissues optically transparent while preserving their three-
dimensional molecular and cellular architecture and facilitate deep imaging of large volumes 
(e.g., via confocal or light-sheet microscopy)23. Cleared tissues are compatible with endogenous 
fluorophores including commonly used markers like GFP3,22,24, eYFP22, and tdTomato24. 
However, some fluorescent signals, such as those from mTurquoise2, mNeonGreen, and 
mRuby2, can deteriorate in chemical clearing reagents. To visualize these reporters, we 
suggest using optical clearing methods like RIMS (refractive index matching solution)24 or 
ScaleSQ25 (Figs. 3a and c, and 4b-c), or commercially available mounting media like Prolong 
Diamond Antifade (Thermo Fisher Scientific, cat. no. P36965)2 (Fig. 2). See the Anticipated 
Results section for details on expected outcomes when using fluorescent reporters. 
We recognize that fluorescent labelling is not desired or feasible for every application. In 
such cases, users must identify the appropriate method(s) for examining transduced cells, 
which may include molecular (e.g., qPCR or Western blot), histological (e.g. with antibodies, 
small molecule dyes, or molecular probes) or functional (e.g., optical imaging) approaches. 
 
Limitations of the method 
A major limitation of AAV capsids, including AAV-PHP variants, is their relatively small 
packaging capacity (<5 kb). Some elements of the rAAV genome, such as the WPRE (see 
legend in Figure 5), can be truncated26 or removed27,28 to accommodate larger genetic 
components. The development of smaller promoters29,30 and dual expression systems31, in 
which genetic elements are split between two or more viruses (requiring efficient 
cotransduction), have also enabled the delivery of larger genomes. Continued development of 
these approaches will help bypass restrictions on rAAV genome size.  
Intravenous administration of AAVs also presents unique challenges. For example, 
systemic transduction may be undesirable for applications in which highly restricted gene 
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expression is vital to the experimental outcome. Possible off-target transduction, due to the 
broad tropism of AAV-PHP variants and/or lack of compatible cell type-specific promoters, can 
be reduced by microRNA (miRNA)-mediated gene silencing. Sequences complementary to 
miRNAs expressed in off-target cell populations can be introduced into the 3’ UTR of the rAAV 
genome (Fig. 5); this has been shown to reduce off-target transgene expression and restrict 
expression to cell types of interest32,33. 
Another challenge of systemic delivery is that it requires a high viral load, which can illicit 
an immune response against the capsid and/or transgene and reduce transduction efficiency in 
vivo34. Immunogenicity of AAVs may be exacerbated by empty capsid contamination in viral 
preparations35,36. The viral purification protocol (Steps 15-31) provided here reduces, but does 
not eliminate, empty capsids (Fig. 6b). If this poses a concern for specific applications, viruses 
can be purified using an alternative approach7,8,37.  
Lastly, generating viruses for systemic administration may impose a financial burden on 
laboratories due to the doses of virus required. Nevertheless, viral-mediated gene delivery is 
inexpensive compared to creating and maintaining transgenic animals. Moreover, intravenous 
injection is faster, less invasive, and less technically demanding than other routes of AAV 
administration, such as stereotaxic injection, thereby eliminating the need for specialized 
equipment and survival surgery training. 
 
Applications of the method  
We anticipate that AAV-PHP capsids can be used with the growing pAAV plasmid repository 
available through Addgene and elsewhere to enable a wide range of biomedical applications 
(Fig. 5 and Table 1). Below, we highlight a few current and potential applications of this method.  
 
Anatomical mapping. Fluorescent reporters are commonly used for cell type-specific mapping 
and phenotyping2,38,39 (Figs. 2-4). AAV-mediated multicolor labeling (e.g., Brainbow40) is 
especially advantageous for anatomical mapping approaches that require individual cells in the 
same population to be distinguished from one another. We and others have demonstrated the 
feasibility of this approach in the brain2,40, retina40, heart (Figs. 4b and c), and gut2, as well as 
peripheral ganglia (Fig. 3c). Spectrally distinct labeling is well-suited for studying the 
organization of cells (e.g., cardiomyocytes (Fig. 4b)) in healthy and diseased tissues and long-
range tract tracing of individual fibers through extensive neural networks (e.g., the enteric2 or 
cardiac nervous systems (Fig. 4c)). 
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Functional mapping. AAV-PHP capsids are also relevant for probing cell function. AAV-PHP.B 
was previously used to target distinct neural circuits throughout the brain for chemogenetic17 
and optical imaging applications19,20. We predict that AAV-PHP viruses will be beneficial for 
manipulating neural networks that are typically difficult to access, such as peripheral circuits 
controlling the heart (Fig. 4d), lungs41, or gut42. AAV-PHP variants could also be utilized to 
interrogate the function of non-neuronal cell types including cardiomyocytes43, pancreatic beta 
cells44,45, and hepatocytes46. Harnessing AAV-PHP viruses to modulate cell physiology may 
reveal novel roles for different cells in regulating organ function and/or animal behavior.  
 
Gene expression, silencing, and editing. AAV-PHP viruses are well-suited for assessing 
potential therapeutic strategies that would benefit from organ-wide or systemic transgene 
expression. Recently, AAV-PHP.B was used to treat17 and model18 neurodegenerative diseases 
with widespread pathology. Other potential applications include gene editing (e.g., via 
CRISPR47,48) or silencing (e.g., via short hairpin RNA (shRNA)49,50); importantly, these 
approaches could be utilized to broadly and noninvasively manipulate cells in both healthy and 
diseased states for either basic research or therapeutically motivated studies. 
 
Summary 
Systemically delivered AAV-PHP viruses provide efficient, noninvasive, and long-term gene 
transfer to cell types throughout the adult CNS, PNS, and visceral organs. Together with the use 
of custom rAAV genomes (Fig. 5 and Table 1), researchers can target genetic elements to 
defined cell populations for diverse applications.  
 
MATERIALS 
REAGENTS 
Plasmid DNA preparation  
● Plasmids, supplied as bacterial stabs (Addgene; see Table 1 for plasmids used in this and 
related work) CRITICAL Three plasmids (pAAV, capsid, and pHelper) are required for 
transfection (Fig. 1). 
● Agarose (Amresco, cat. no. N605-250G) 
● Antibiotics (e.g., carbenicillin disodium salt, Alfa Aesar, cat. no. J61949-06; all plasmids 
used in this work carry antibiotic resistance genes to ampicillin/carbenicillin) 
● DNA ladder, 2-log, 0.1-10.0 kb (New England Biolabs, cat. no. N0550S) 
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● Lysogeny broth (LB) (Amresco, cat. no. J106-1KG); for large-scale plasmid preparations, 
such as maxi- and giga-preps, we typically use Plasmid+ media (Thomson Instrument 
Company, cat. no. 446300), an enriched media formulated to support higher cell densities 
and plasmid yields compared to LB    
● Lysogeny broth (LB) with agar (Sigma-Aldrich, cat. no. L3147-1KG)  
● NucleoBond Xtra Maxi Endotoxin-Free (EF) plasmid purification kit (Macherey-Nagel, cat. 
no. 740424.50) CRITICAL Triple transient transfection requires large amounts of capsid 
(22.8 µg/dish) and pHelper plasmid DNA (11.4 µg/dish) (Supplementary Table 2, sheet 
‘Detailed calculations’); isolating these plasmids may be more convenient with a giga-
scale purification kit (NucleoBond PC 10000 EF, Macherey-Nagel, cat. no. 740548). All 
plasmids should be purified under endotoxin-free conditions. Endotoxin contamination in 
plasmid preparations can reduce transfection efficiency, and contaminating endotoxins in 
viral preparations could elicit immune reactions in mammals in vivo. 
● Restriction enzymes, including SmaI (New England Biolabs, cat. no. R0141S); used for 
verifying plasmid and ITR integrity 
● Sequencing primers (Integrated DNA Technologies); used for verifying plasmid integrity 
● SYBR Safe DNA gel stain (Invitrogen, cat. no. S33102) 
● Tris-acetate-EDTA (TAE) buffer, 50X (Invitrogen, cat. no. B49) 
 
Cell culture 
● Human embryonic kidney (HEK) cells, 293 or 293T (ATCC, cat. no. CRL 1573 or CRL 
3216) CAUTION HEK cells pose a moderate risk to laboratory workers and the 
surrounding environment and must be handled according to governmental and 
institutional regulations. Experiments involving HEK cells are performed using Biosafety 
Level 2 practices as required by the California Institute of Technology and the U.S. Centers 
for Disease Control and Prevention. The cell line identity has not been validated, nor do 
we routinely test for mycoplasma. CRITICAL HEK293 and HEK293T cells constitutively 
express two adenoviral genes, E1a and E1b, which are required for AAV production in 
these cells6; we do not recommend using an alternative producer cell line with this 
protocol.  
● Dulbecco’s Modified Eagle Medium (DMEM), high glucose, GlutaMAX supplement, 
pyruvate (Gibco, cat. no. 10569-044) 
● Ethanol, 70% (v/v); prepare from absolute ethanol (J.T. Baker, cat. no. 8025) CAUTION 
Ethanol is flammable. 
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● Fetal bovine serum (FBS) (GE Healthcare, cat. no. SH30070.03) CRITICAL Aliquot and 
store at -20˚C for up to 1 year. Avoid freeze/thaw cycles. 
● MEM Non-Essential Amino Acids (NEAA) solution, 100X (Gibco, cat. no. 11140-050) 
● Penicillin-Streptomycin (Pen-Strep), 5000 U/ml (Gibco, cat. no. 15070-063) CRITICAL 
Aliquot and store at -20˚C for up to 1 year. Avoid freeze/thaw cycles.   
● TrypLE Express enzyme, 1X, phenol red (Gibco, cat. no. 12605-036) 
 
Transfection 
● Plasmid DNA CRITICAL We use a pAAV:capsid:pHelper plasmid ratio of 1:4:2 based on 
µg of DNA. We use 40 µg of total DNA per 150 mm dish (5.7 µg of pAAV, 22.8 µg of 
capsid, and 11.4 µg of pHelper) (Supplementary Table 2, sheet ‘Detailed calculations’). 
● Polyethylenimine (PEI), linear, MW 25000 (Polysciences, Inc., cat. no. 23966-2) 
● Water for Injection (WFI) for cell culture (Gibco, cat. no. A1287304) 
● 1X Dulbecco’s PBS (DPBS), no calcium, no magnesium (Gibco, cat. no. 14190-250) 
● 1 N HCl solution, suitable for cell culture (Sigma-Aldrich, cat. no. H9892) CAUTION HCl 
is corrosive. Use personal protective equipment.   
 
AAV production  
● Bleach, 10% (v/v); prepare fresh from concentrated liquid bleach (e.g., Clorox) CRITICAL 
AAV-contaminated materials must be disinfected with bleach prior to disposal; ethanol is 
not an effective disinfectant. Experiments involving AAVs follow a standard operating 
procedure in which contaminated equipment, surfaces, and labware are disinfected for 10 
min with 10% bleach. AAV waste disposal should be conducted according to federal, state, 
and local regulations. 
● Dry ice; optional 
● KCl (any)  
● MgCl2 (any) 
● NaCl (any) 
● OptiPrep (60% (w/v) iodixanol) density gradient media (Cosmo Bio USA, cat. no. AXS-
1114542-5) 
● Phenol red solution (Millipore, cat. no. 1072420100) 
● Pluronic F-68 non-ionic surfactant, 100X (Gibco, cat. no. 24040-032); optional  
● Polyethylene glycol (PEG), MW 8000 (Sigma-Aldrich, 89510-1KG-F) 
● Salt-active nuclease (SAN) (ArcticZymes, cat. no. 70910-202) 
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● Tris base (any)   
● Ultrapure DNAse/RNAse-free distilled water (Invitrogen, cat. no. 10977-023) 
● Water for Injection (WFI) for cell culture (Gibco, cat. no. A1287304) 
● 1X Dulbecco’s PBS (DPBS), no calcium, no magnesium (Gibco, cat. no. 14190-250) 
 
AAV titration 
● AAVs 
● CaCl2 (any) 
● DNAse I recombinant, RNAse-free (Sigma-Aldrich, cat. no. 4716728001) 
● HCl, 37% (wt/wt) (Sigma-Aldrich, cat. no. 320331-500ML)  
● MgCl2 (any) 
● NaCl (any) 
● N-lauroylsarcosine sodium salt (Sigma-Aldrich, cat. no. L9150-50G) 
● Plasmid DNA containing the target sequence (e.g., pAAV-CAG-eYFP, Addgene ID 
104055); used for preparing the DNA standard stock CRITICAL The plasmid used to make 
the DNA standard must contain the same target sequence as the pAAV plasmid used to 
generate virus. The target sequence must be within the rAAV genome; we typically amplify 
a portion of the WPRE in the 3’ UTR of pAAVs (see legend in Fig. 5). 
● Primers corresponding to the target sequence (Integrated DNA Technologies)  
WPRE-forward: GGCTGTTGGGCACTGACAAT  
WPRE-reverse: CCGAAGGGACGTAGCAGAAG  
CRITICAL The proximity of the primer binding sites to the ITRs can affect titering results; 
therefore, titers measured with different primers or across laboratories may not be directly 
comparable. 
● Proteinase K, recombinant, PCR grade (Sigma-Aldrich, cat. no. 03115828001) 
● Qubit dsDNA HS assay kit (Invitrogen, cat. no. Q32854) 
● ScaI-HF restriction enzyme (New England Biolabs, cat. no. R3122S) or other enzyme that 
cuts outside of the rAAV genome and within the pAAV backbone 
● SYBR green master mix (Roche Diagnostics, cat. no. 04913850001) 
● Tris base (any) 
● Ultrapure DNAse/RNAse-free distilled water (Invitrogen, cat. no. 10977-023)  
● Ultrapure EDTA, 0.5 M, pH 8.0 (Invitrogen, cat. no. 15575-020)   
 
Intravenous (retro-orbital) injection 
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● AAVs 
● Animals to be injected. This protocol describes the production of AAVs for intravenous 
delivery to 6-8 week old wild-type (C57BL/6J), ChAT-IRES-Cre (Jackson Laboratory, 
stock no. 028861, heterozygous), TH-IRES-Cre (European Mutant Mouse Archive, stock 
no. EM00254, heterozygous), and TRPV1-IRES-Cre mice (Jackson Laboratory, stock no. 
017769, homozygous). CAUTION Experiments on vertebrates must conform to all 
relevant governmental and institutional regulations. Animal husbandry and experimental 
procedures involving mice were approved by the Institutional Animal Care and Use 
Committee (IACUC) and the Office of Laboratory Animal Resources at the California 
Institute of Technology.  
● Bleach, 10% (v/v) prepared fresh, or equivalent disinfectant (e.g., Accel TB surface 
cleaner, Health Care Logistics, cat. no. 18692) 
● Isoflurane, USP (Piramal Healthcare, 66794-017-25) CAUTION Isoflurane is a 
halogenated anesthetic gas associated with adverse health outcomes in humans and 
must be handled according to governmental and institutional regulations. To reduce the 
risk of occupational exposure during rodent anesthesia, waste gas is collected in a 
biosafety cabinet using a charcoal scavenging system as approved by the California 
Institute of Technology.  
● Proparacaine hydrochloride ophthalmic solution, USP, 0.5% (Akorn Pharmaceuticals, cat. 
no. 17478-263-12)  
● 1X Dulbecco’s PBS (DPBS), no calcium, no magnesium (Gibco, cat. no. 14190-250) 
------------------------------------------------------------------------------------------------------------------------------- 
EQUIPMENT 
Plasmid DNA preparation equipment  
● Autoclave (any, as available) 
● Bunsen burner and lighter (Fisher Scientific, cat. nos. 03-917Q and S41878A) 
● Centrifuge (see requirements for chosen plasmid purification kit) 
● Gel electrophoresis system (Bio-Rad horizontal electrophoresis system)   
● Gel imaging system (Bio-Rad Gel Doc EZ model) 
● Incubating shaker (Eppendorf I24 model) 
● Incubator (Thermo Fisher Scientific Heratherm model) or 37˚C warm room 
● Sequence editing and annotation software (e.g., Lasergene by DNASTAR, SnapGene by 
GSL Biotech, or VectorNTI by Thermo Fisher Scientific)  
● Spectrophotometer (Thermo Fisher Scientific NanoDrop model)  
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Plasmid DNA preparation supplies 
● Petri dishes, 100 mm x 15 mm (Corning, cat. no. 351029) 
● Test tubes, 14 ml (Corning, cat. no. 352059) 
● Ultra Yield flasks and AirOtop seals, 250 ml (Thomson Instrument Company, cat. nos. 
931144 and 899423); use with Plasmid+ media. Alternatively, use LB and standard 
Erlenmeyer flasks. 
 
AAV production equipment 
● Biological safety cabinet CAUTION HEK293T cells and AAVs are biohazardous materials 
and must be handled according to governmental and institutional regulations. All 
experiments involving the aforementioned materials are performed in a Class II biosafety 
cabinet with annual certification as required by the California Institute of Technology and 
the U.S. Centers for Disease Control and Prevention. 
● Centrifuge (any, provided the instrument can reach speeds up to 4,000 x g, refrigerate to 
4˚C, and accommodate 250 ml conical centrifuge tubes; we use the Beckman Coulter 
Allegra X-15R model) 
● Fluorescence microscope for cell culture (Zeiss Axio Vert.A1 model)  
● Incubator for cell culture, humidified at 37˚C with 5% CO2 (Thermo Fisher Scientific 
Heracell 240i model) 
● Laboratory balance (any, with a readability of 5-10 mg) 
● Support stand with rod and clamp (VWR International, cat. nos. 12985-070, 60079-534, 
and 89202-624) (Fig. 7f)  
● Ultracentrifuge (any preparative ultracentrifuge for in vitro diagnostic use; we use the 
Beckman Coulter Optima XE-9 model with the Type 70Ti rotor) CAUTION During 
ultracentrifugation, rotors are subjected to enormous forces (up to 350,000 x g in this 
protocol). Rotor failure can have catastrophic consequences including irreparable damage 
to the centrifuge and laboratory and fatal injuries to personnel. Inspect rotors for signs of 
damage or weakness prior to each use, and always follow the manufacturer’s instructions 
while operating an ultracentrifuge.  
● Water bath (Fisher Scientific Isotemp model)  
AAV production supplies 
● Amicon Ultra-15 centrifugal filter devices, 100 KDa molecular weight cutoff (Millipore, cat. 
no. UFC910024) 
● Barrier pipet tips, 1000 µl (Genesee Scientific, cat. no. 23-430) 
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● Cell scrapers, 25 cm handle x 3 cm blade (Corning, cat. no. 353089) 
● Conical centrifuge tubes, 50 ml and 250 ml (Corning, cat. nos. 352098 and 430776) 
● Empty, sterile media bottles  
● OptiSeal tubes (Beckman Coulter, cat. no. 361625); includes black caps  
● OptiSeal tube kit (Beckman Coulter, cat. no. 361662); includes a tube rack, spacers, and 
spacer and tube removal tools 
● Pipet Aid XL portable pipetting device (Drummond, cat. no. 4-000-105) CRITICAL Use a 
pipetting device with precise control, which is essential for pouring the density gradients 
in Step 16.  
● pH indicator strips (Millipore, cat. nos. 109532 and 109584) 
● Screw-cap vials, 1.6 ml (National Scientific Supply Co., cat. no. BC16NA-PS) 
● Serological pipets, 2 ml, 5 ml, 10 ml, 25 ml, and 50 ml (Corning, cat. no. 356507 and 
Genesee Scientific, cat. nos. 12-102, 12-104, 12-106, and 12-107) CRITICAL Only 
Corning brand 2 ml serological pipets consistently fit into OptiSeal tubes while pouring the 
density gradients in Step 16. Alternatively, attach a small piece of clear tubing (6 mm) 
(e.g., Tygon Tubing) to a 5 ml pipet to pour the gradients. 
● Stericup sterile vacuum filtration system, 0.22 µm, 500 ml and 1 L (Millipore, cat. nos. 
SCGPU05RE and SCGPU11RE) 
● Sterile bottles, 500 ml (VWR International, cat. no. 89166-106) 
● Syringes, 5 ml and 10 ml (BD, cat. nos. 309646 and 309604)  
● Syringe filter unit, 0.22 µm (Millipore, cat. no. SLGP033RS)  
● Tissue culture dishes, 150 mm x 25 mm (Corning, cat. no. 430599) 
● 16 G x 1 ½ in needles (BD, cat. no. 305198) 
 
AAV titration equipment 
● Centrifuge (Eppendorf, 5418 model) 
● Dry bath and heating blocks (Fisher Scientific Isotemp models) 
● PCR plate spinner (VWR International, cat. no. 89184) or centrifuge equipped with plate 
adapters 
● Quantitative PCR machine (any) 
● Qubit 3.0 fluorometer (Invitrogen, cat. no. Q33216) 
AAV titration supplies 
● Barrier pipet tips, 10 µl, 20 µl, 200 µl, and 1000 µl (Genesee Scientific, cat. nos. 23-401, 
23-404, 23-412, and 23-430) 
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● DNA clean-up kit, for purification of up to 25 µg of DNA standard (Zymo Research, cat. 
no. D4033)  
● Microcentrifuge tubes, 1.5 ml DNA/RNA LoBind (Eppendorf, cat. no. 86-923) 
● Qubit assay tubes (Invitrogen, cat. no. Q32856) 
● Sealing film for 96-well PCR plates (Genesee Scientific, cat. no. 12-529) 
● Stericup sterile vacuum filtration system, 0.22 µm, 250 ml (Millipore, cat. no. 
SCGPU02RE) 
● Sterile bottles, 250 ml (VWR International, cat. no. 89166-104) 
● 96-well PCR plates (Genesee Scientific, cat. no. 24-310W) 
 
Intravenous (retro-orbital) injection equipment 
● Animal anesthesia system (VetEquip, cat. nos. 901806, 901807, or 901810) CRITICAL 
Most animal facilities provide anesthesia systems equipped with an induction chamber, 
isoflurane vaporizer, nose cone, and waste gas scavenging system. In our experience, a 
mobile anesthesia system is most convenient for administering AAVs in a biosafety 
cabinet. 
Intravenous (retro-orbital) injection supplies 
● Activated charcoal adsorption filters (VetEquip, cat. no. 931401) 
● Insulin syringes with permanently attached needles, 31 G x 5/16 in (BD, cat. no. 328438) 
● Oxygen gas supply (any) 
● Screw-cap vials, 1.6 ml (National Scientific Supply Co., cat. no. BC16NA-PS) 
--------------------------------------------------------------------------------------------------------------------- 
REAGENT SETUP 
CRITICAL All solutions should be prepared in a biosafety cabinet using sterile technique and 
endotoxin-free reagents and supplies. Glassware, stir bars, and pH meters are not endotoxin-
free; autoclaving does not eliminate endotoxins. To prepare solutions, use pH indicator strips, 
dissolve reagents by heating and/or inverting to mix, and use demarcations on bottles to bring 
solutions up to the final volume. Reagents can be weighed outside of a biosafety cabinet since 
all solutions are filter sterilized before use.  
 
Plasmid DNA Grow bacterial stocks in LB or Plasmid+ media containing the appropriate 
selective antibiotic. Use a large-scale endotoxin-free plasmid purification kit to isolate plasmids; 
elute plasmid DNA with the supplied Tris-EDTA (TE) buffer. Measure DNA purity and 
concentration using a spectrophotometer and freeze at -20˚C or -80˚C for up to several years. 
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CRITICAL Always verify the integrity of purified plasmids by sequencing and restriction digest 
before proceeding with downstream applications. pAAV plasmids contain inverted terminal 
repeats (ITRs) (Fig. 5) that are prone to recombination in E. coli. pAAVs should be propagated 
in recombination deficient strains such as NEB Stable (New England Biolabs, cat. no. C3040H), 
Stbl3 (Invitrogen, cat. no. C737303), or SURE 2 competent cells (Agilent, cat. no. 200152) to 
prevent unwanted recombination. After purification, pAAVs should be digested with SmaI to 
confirm the presence of ITRs, which are required for replication and encapsidation of the viral 
genome; use sequence editing and annotation software to determine expected band sizes. Note 
that it is difficult to sequence through the secondary structure of ITRs51; avoid ITRs when 
designing sequencing primers. 
 
DMEM + 5% (v/v) FBS Add 25 ml of FBS, 5 ml of NEAA, and 5 ml of Pen-Strep to a 500 ml 
bottle of DMEM. Invert to mix and store at 4˚C for up to several months. The resulting cell 
culture media should have a final concentration of 5% (v/v) FBS, 1X NEAA, and 50 U/ml Pen-
Strep.   
 
Cell culture Thaw HEK293T cells according to the manufacturer’s recommendations. Passage 
cells using either TrypLE Express enzyme or a standard trypsinization protocol for adherent 
cultures52. Seed cells in 150 mm tissue culture dishes with a final volume of 20 ml of DMEM + 
5% FBS per dish. Maintain in a cell culture incubator at 37˚C with 5% CO2. CRITICAL We 
suggest a passage ratio of 1:3 (i.e., divide one dish of cells into three new dishes of cells every 
other day) when expanding cells for viral production; split cells at 1:2 (or 6 x 104 cells/cm2) 24 hr 
before transfection. Always use sterile technique.  
 
PEI stock solution Pipet 50 ml of WFI water into a 50 ml conical centrifuge tube for later use. 
Add 323 mg of PEI to the remaining 950 ml bottle of WFI water and adjust the pH to 2-3 by 
adding 1 N HCl suitable for cell culture, keeping track of the volume of HCl added. Heat in a 
37˚C water bath for several hours (or overnight) and occasionally shake to mix. Once dissolved, 
add reserved WFI water to a total volume of 1 L. Filter sterilize, aliquot to 50 ml conical 
centrifuge tubes, and store at -20˚C for up to 1 year. We routinely freeze/thaw our PEI aliquots. 
CRITICAL Both our PEI stock solution recipe and PEI calculations (Supplementary Table 2, 
sheet ‘Detailed calculations’) are based on ref. 4.  
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PEI + DPBS master mix Thaw PEI in a 37˚C water bath. Bring PEI to RT and vortex to mix. 
Add PEI and DPBS to a 50 ml conical centrifuge tube and vortex again to mix. Use 
Supplementary Table 2 (sheet ‘Transfection calculator’) to calculate the volumes of PEI (cell 
I9) and DPBS (cell J9) needed. CRITICAL Prepare fresh the day of transfection. 
 
DNA + DPBS Bring plasmid DNA to RT and briefly vortex to mix. For each viral prep, add DNA 
and DPBS to a 50 ml conical centrifuge tube and use a P1000 pipet to mix. Use 
Supplementary Table 2 (sheet ‘Transfection calculator’) to calculate the quantities of DNA 
(e.g., cells E9+E11+E13) and DPBS (e.g., cell F9) needed. CRITICAL Prepare fresh the day of 
transfection. Re-measure plasmid DNA concentrations immediately prior to use; multiple 
freeze/thaw cycles may cause DNA degradation.  
 
SAN digestion buffer Add 29.22 g of NaCl, 4.85 g of Tris base, and 952 mg of MgCl2 to a 1 L 
bottle of WFI water and shake to mix. Filter sterilize and store at RT for up to several months. 
The resulting SAN digestion buffer should have a final pH of 9.5-10.0 and a final concentration 
of 500 mM NaCl, 40 mM Tris base, and 10 mM MgCl2.  
 
SAN + SAN digestion buffer Add 100 U of SAN per ml of SAN digestion buffer; pipet to mix. 
CRITICAL Prepare fresh prior to use.  
 
40% (w/v) PEG stock solution Decant approximately 500 ml of WFI water into a 500 ml sterile 
bottle for later use. Add 146.1 g of NaCl to the remaining 500 ml bottle of WFI water and 
shake/heat until dissolved. Once completely dissolved, add 400 g of PEG and heat at 37˚C for 
several hours to overnight. Add reserved WFI water to a total volume of 1 L. Filter sterilize and 
store at RT for up to several months. The resulting stock solution should have a final 
concentration of 2.5 M NaCl and 40% (w/v) PEG. CRITICAL Prepare in advance. To expedite 
the procedure, heat the solution at 65˚C until the PEG is dissolved. The solution will appear 
turbid but no flecks of PEG should remain; the mixture will become clear upon cooling. 
CRITICAL Pre-wet the entire filter surface with a minimal volume of water prior to adding the 
solution. This solution is extremely viscous and will take 1-2 h to filter.  
 
DPBS + high salt Add 29.22 g of NaCl, 93.2 mg of KCl, and 47.6 mg of MgCl2 to a 500 ml 
bottle of DPBS and shake to mix. Filter sterilize and store at RT for up to several months. The 
resulting buffer should have a final concentration of 1 M NaCl (in addition to the salt in the 
DPBS), 2.5 mM KCl, and 1 mM MgCl2.  
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DPBS + low salt Add 2.92 g of NaCl, 93.2 mg of KCl, and 47.6 mg of MgCl2 to a 500 ml bottle 
of DPBS and shake to mix. Filter sterilize and store at RT for up to several months. The 
resulting buffer should have a final concentration of 100 mM NaCl (in addition to the salt in the 
DPBS), 2.5 mM KCl, and 1 mM MgCl2. 
 
Iodixanol density step solutions (15%, 25%, 40%, and 60% (w/v) iodixanol) For each step, 
add iodixanol, DPBS + high salt or DPBS + low salt, and phenol red (if applicable) to a 50 ml 
conical centrifuge tube. Briefly invert or vortex to mix. Use Supplementary Table 3 to 
determine the volumes of each reagent needed. The 25% and 60% steps contain phenol red, 
which turns the solutions red and yellow, respectively, and facilitates clear demarcation of the 
gradient boundaries (Fig. 7). CRITICAL Prepare fresh the day of AAV purification. Alternatively, 
prepare up to 1 d in advance; store under sterile conditions at RT and protect from light. Do not 
pour the density gradients until Step 16. 
 
1 M Tris-Cl stock solution Pipet 80 ml of Ultrapure or WFI water into a 250 ml sterile bottle. 
Add 12.11 g of Tris base and 7 ml of concentrated HCl and shake to mix; fine adjust the pH to 
7.5 by adding more concentrated HCl. Add water to a total volume of 100 ml. Filter sterilize and 
store at RT for up to several months.  
 
DNAse digestion buffer Decant 250 ml of Ultrapure water into a 250 ml sterile bottle. Add 55.5 
mg of CaCl2, 2.5 ml of 1 M Tris-Cl stock solution, and 238 mg of MgCl2 and shake to mix. Filter 
sterilize and store at RT for up to several months. The resulting buffer should have a final 
concentration of 2 mM CaCl2, 10 mM Tris-Cl, and 10 mM MgCl2.  
 
DNAse I + DNAse digestion buffer Add 50 U of DNAse I per ml of digestion buffer; pipet to 
mix. CRITICAL Prepare fresh prior to use.  
 
Proteinase K solution Decant 250 ml of Ultrapure water into a 250 ml sterile bottle. Add 14.61 
g of NaCl and shake to mix. Add 2.5 g of N-lauroylsarcosine sodium salt to the mixture and 
gently swirl to mix; N-lauroylsarcosine sodium salt is a surfactant and will generate bubbles 
during vigorous mixing. Filter sterilize and store at RT for up to several months. The resulting 
solution should have a final concentration of 1 M NaCl and 1% (w/v) N-lauroylsarcosine sodium 
salt.  
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Proteinase K + proteinase K solution Add 100 µg of proteinase K per ml of solution; pipet to 
mix. CRITICAL Prepare fresh prior to use.  
 
DNA standard stock Set up a single 50 µl restriction digest reaction; use 60-80 U (3-4 µl) of 
ScaI (or other suitable enzyme) to linearize 20 µg of the plasmid DNA containing the target 
sequence. Run a small amount of the reaction on an agarose gel to ensure complete digestion. 
Purify the reaction using two DNA clean-up columns. Measure the DNA concentration (ng/µl) 
using a spectrophotometer. Dilute to approximately 5-10 x 109 single-stranded (ss) DNA 
molecules/µl and use the Qubit assay to verify the concentration (ng/µl). Divide into 20 µl 
aliquots and freeze at -20˚C for up to 1 year. CRITICAL Prior to preparing the standard, use 
sequence editing and annotation software to confirm that the plasmid contains a single ScaI site 
in the ampicillin resistance gene. Refer to ref. 10 and use Supplementary Table 4 (cell B13) to 
calculate the number of ssDNA molecules in a given plasmid. We typically use pAAV-CAG-
mNeonGreen to prepare the standard; following restriction digest we dilute the linearized 
plasmid to 10 ng/µl, which corresponds to 6.6 x 109 ssDNA molecules/µl.    
 
DNA standard dilutions Prepare three sets of 8 (1:10) serial dilutions of the DNA standard 
stock. For each set, begin by pipetting 5 µl of the standard into 45 µl of Ultrapure water 
(standard #8). Mix by pipetting and proceed with the 7 remaining dilutions (standard #7 to 
standard #1). The final concentrations of the standard dilutions should range from 5-10 x 108 
(standard #8) to 5-10 x 101 (standard #1) ssDNA molecules/µl. CRITICAL Prepare fresh in 
DNA/RNA LoBind microcentrifuge tubes immediately prior to use; at low concentrations, the 
linearized DNA is prone to degradation and/or sticking to the walls of the tube10. One 20 µl 
aliquot of the DNA standard stock will provide enough DNA for preparing the dilutions and 
verifying the concentration via the Qubit assay prior to qPCR.  
 
qPCR master mix Prepare a qPCR master mix for the total number of reactions (i.e., wells) 
needed. One reaction requires 12.5 µl of SYBR green master mix, 9.5 µl of Ultrapure water, and 
0.5 µl of each primer (from a 2.5 µM stock concentration), for a total of 23 µl/well. Briefly vortex 
to mix. CRITICAL Prepare fresh prior to use. 
------------------------------------------------------------------------------------------------------------------------------- 
EQUIPMENT SETUP 
Clamp setup for AAV purification Attach the rod to the support stand. Secure the clamp 
approximately 25-30 cm above the stand (Fig. 7f). 
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Anesthesia system Place the induction chamber, nose cone, and waste gas scavenging 
system (e.g., activated charcoal adsorption filters) inside a biosafety cabinet. We recommend 
using a mobile anesthesia system in which the isoflurane vaporizer and oxygen supply remain 
outside of the cabinet workspace. Connect the associated tubing such that the input is from the 
vaporizer/oxygen supply and the output is to the charcoal scavenging device53. 
--------------------------------------------------------------------------------------------------------------------- 
PROCEDURE 
CRITICAL The entire procedure spans 8 d, excluding pause points and the time required to 
evaluate transgene expression (Fig. 6a). There are no pause points between days 1 and 5, until 
Step 11; once cells have been transfected, AAVs are harvested on days 3 and 5. Plan 
accordingly during this time window. 
  
Triple transient transfection of HEK293T cells  
TIMING 1-2 h 
CRITICAL For capsids that package well (i.e., AAV9, AAV-PHP.B, AAV-PHP.eB, and AAV-
PHP.S), the PEI transfection protocol typically yields over 1 x 1012 vector genomes (vg) per 150 
mm dish, as measured post-purification2,3. Before proceeding with the protocol, determine the 
number of dishes needed per viral prep and use Supplementary Table 2 (sheet ‘Transfection 
calculator’) to calculate the quantities of PEI, DPBS, and plasmid DNA required for transfection. 
Skip to Step 43 if custom AAVs were obtained elsewhere. 
 
1. 24 h before transfection, seed cells in 150 mm dishes to attain 80-90% confluency the 
next day52.   
 
2. At the time of transfection, make the PEI + DPBS master mix and the DNA + DPBS 
solution for each viral prep (see REAGENT SETUP and Supplementary Table 2, sheet 
‘Transfection calculator’). Using a serological pipet, add the required volume of the PEI + 
DPBS master mix (e.g., ‘Transfection calculator’ cell G9) to the DNA + DPBS solution 
(e.g., ‘Transfection calculator’ cells E9+E11+E13+F9); immediately vortex the resulting 
transfection solution to mix. Add 2 ml of the transfection solution dropwise to each dish 
and swirl to mix before returning to the cell culture incubator.  
CRITICAL STEP The transfection solution will appear slightly cloudy due to the formation 
of DNA-PEI complexes4,5. 
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CRITICAL STEP Users may opt to run a positive transfection/virus production control (e.g. 
pAAV-CAG-eYFP, Addgene ID 104055); this is especially important if using an untested 
rAAV genome. 
TROUBLESHOOTING 
 
3. Change the media 12-24 h post-transfection by aspirating the old media and replacing it 
with 20 ml of fresh, warmed DMEM + 5% FBS.  
CRITICAL STEP Do not allow cells to remain without media for more than a few min. To 
protect cells from unwanted stress, we aspirate media from 5 plates at a time and promptly 
replace it with new media. PEI is moderately cytotoxic5 and cell death up to 20% is 
common. Do not allow the media to go unchanged for more than 24 h post-transfection. 
Failure to change media in a timely manner will result in poor cell health and low titers.   
CRITICAL STEP Beginning 72 h post-transfection, examine cells under a fluorescence 
microscope to assess fluorescent protein expression, if applicable. Note that expression 
from the rAAV genome does not necessarily correlate with final viral yield and will depend 
on the reporter and/or promoter under investigation. 
TROUBLESHOOTING  
 
AAV harvest 
TIMING 5 d 
CAUTION While not infectious, recombinant AAVs are potent gene delivery vehicles and must 
be handled according to governmental and institutional regulations. The safety of packaged 
transgenes (e.g., oncogenic genes) should be carefully considered. Perform all procedures in a 
certified biosafety cabinet and clean AAV-contaminated equipment, surfaces, and labware with 
fresh 10% bleach prior to disposal. 
CRITICAL Carefully label all tubes and replace gloves, pipets, and cell scrapers between viral 
preps to avoid cross-contamination. Refer to Figure 6b for a schematic of the AAV harvest 
procedure.  
  
4. Harvest the cell culture media 72 h (3 d) post-transfection. Tilt each dish at a 30˚ angle 
and use a 25 ml serological pipet to collect the media. Store in an empty media bottle or 
sterile 500 ml bottle at 4˚C until Step 6. Replace the media with 20 ml of fresh, warmed 
DMEM + 5% FBS. 
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CAUTION Tilt dishes away from the front grill of the biosafety cabinet to prevent media 
from spilling out of the biosafety cabinet. 
CRITICAL STEP To avoid cross-contamination, harvest the media from one viral prep at 
a time.  
CRITICAL STEP For AAV-PHP production in HEK293T cells, the media at 72 h post-
transfection contains approximately 2 x 1011 vg per dish, or approximately 20% of the 
expected viral yield. Failure to collect and change media at this time point will result in 
poor cell health and low titers. If time is limited, media and cells can be harvested at 72 h 
rather than 120 h (Step 5); however, total yields will be reduced by 30-50%. 
 
5. Harvest the media and cells 120 h (5 d) post-transfection. Use a cell scraper to gently 
scrape the cells into the media. After scraping the first dish, prop it at a 30˚ angle using an 
empty 1.5 ml microcentrifuge tube rack for support. Scrape down the residual cells and 
media such that they are pooled together. Return the dish lid and scrape the next plate; 
prop dishes up against one another along the length of the biosafety cabinet until scraping 
is complete. Use a 25 ml serological pipet to collect the media and cells; transfer to a 250 
ml conical centrifuge tube. 
CAUTION Scrape cells with a forward motion (i.e., away from the front grill of the biosafety 
cabinet) to prevent media and cells from splashing out of the biosafety cabinet. If a spill 
does occur at this or any other step, immediately cover with paper towels and carefully 
saturate the towels with 10% bleach. 
CRITICAL STEP To avoid cross-contamination, harvest the media and cells from one viral 
prep at a time. 
 
6. Combine the media collected at 72 h post-transfection (Step 4) with the media and cells 
collected at 120 h post-transfection (Step 5). For smaller viral preps (1-5 dishes), proceed 
to option A. For larger preps (6-10 dishes), proceed to option B. 
A. Harvest from 1-5 dishes 
i. Pour the media collected in Step 4 into the corresponding 250 ml tube of media 
and cells collected in Step 5. 
B. Harvest from 6-10 dishes 
i. Pour the media collected in Step 4 into a second, empty 250 ml tube. 
CRITICAL STEP Save the bottle from Step 4 for Step 8. 
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7. Centrifuge the media and cells at 2,000 x g for 15 min at RT. Ensure that the tube caps 
are tightly secured. Centrifugation will result in the formation of a cell pellet (Fig. 6b). 
 
8. Pour off the supernatant (i.e., the clarified media) into the corresponding bottle from Step 
4. Allow excess media to drip back down onto the beveled edge of the 250 ml tube; remove 
using a P1000 pipet and combine with the supernatant. Store the supernatant at 4˚C until 
Step 10.  
CRITICAL STEP Failure to remove excess media from the pellet will cause several ml of 
media to dilute the SAN digestion buffer in Step 9. 
 
9. Resuspend the pellet for cell lysis. Prepare 5 ml of SAN + SAN digestion buffer per viral 
prep. 
A. Harvest from 1-5 dishes 
i. Use a 5 ml serological pipet to gently resuspend the pellet in 5 ml of SAN + 
SAN digestion buffer; pipet into a 50 ml tube to finish resuspending the pellet 
(Fig. 6b).  
ii. Incubate in a 37˚C water bath for 1 h and store at 4˚C until Step 14. 
B. Harvest from 6-10 dishes 
i. Use a 10 ml serological pipet to partially resuspend the smaller pellet in 5 ml 
of SAN + SAN digestion buffer. Pipet into the second 250 ml tube containing 
the larger pellet and resuspend together; pipet into a 50 ml tube to finish 
resuspending the pellet (Fig. 6b).  
ii. Incubate in a 37˚C water bath for 1 h and store at 4˚C until Step 14.  
CRITICAL STEP Be sure to collect the entire pellet, which sticks to the walls 
and beveled edges of 250 ml tubes. Save the 250 ml tubes for Step 10. 
CRITICAL STEP The high salt content of SAN digestion buffer lyses cells, 
which release viral particles and nucleic acids into solution. Initially, the cell 
lysate may be viscous and difficult to pipet; SAN will degrade nucleic acids and 
reduce the viscosity after incubation at 37˚C. The pH of the lysate will decrease 
to 8-9 or lower during cell lysis but the lysate should appear pink rather than 
yellow/orange due to residual phenol red (Fig. 6b). Note that expression of 
fluorescent proteins from strong promoters (e.g., CAG) can alter the color of 
the lysate.  
CRITICAL STEP Collect a 30 µl sample from the cell lysate for troubleshooting. 
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TROUBLESHOOTING 
 
10. Retrieve the supernatant collected in Step 8. 
A. Harvest from 1-5 dishes 
i. Pour the supernatant from Step 8 into the corresponding 250 ml tube from Step 
9. 
B. Harvest from 6-10 dishes 
i. Equally divide the supernatant from Step 8 into the two corresponding 250 ml 
tubes from Step 9.  
CRITICAL STEP Collect a 30 µl sample from the media for troubleshooting. 
 
11. Use a 25 ml or 50 ml serological pipet to add 1/5 volume of 40% PEG stock solution to 
the supernatant (i.e., the supernatant should contain a final concentration of 8% PEG 
solution). Tighten the cap and invert 10 times to mix. Incubate on ice for 2 h. 
CRITICAL STEP For AAV production in HEK293T cells, the cell culture media contains a 
significant fraction of the expected yield54. Failure to PEG precipitate AAV particles in the 
media will result in lower viral yields7.   
PAUSE POINT The PEG/media mixture may be incubated at 4˚C overnight. 
 
12. Centrifuge the PEG/media mixture at 4,000 x g for 30 min at 4˚C. Centrifugation will result 
in the formation of a PEG pellet (Fig. 6b). 
 
13. Pour off the supernatant (i.e., the PEG-clarified media) into a used media collection bottle 
for bleaching. Allow excess media to drip back down onto the beveled edge of the 250 ml 
tube; aspirate to remove. 
 
14. Resuspend the PEG pellet. Prepare 1 ml of SAN + SAN digestion buffer per viral prep.  
A. Harvest from 1-5 dishes 
i. Use a P1000 pipet to resuspend the PEG pellet in 1 ml of SAN + SAN digestion 
buffer; pipet into the corresponding lysate from Step 9 (Fig. 6b). 
ii. Incubate in a 37˚C water bath for an additional 30 min.  
B. Harvest from 6-10 dishes  
i. Use a P1000 pipet to partially resuspend one of the PEG pellets in 1 ml of SAN 
+ SAN digestion buffer. Pipet into the second 250 ml tube containing the 
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second pellet and resuspend together; pipet into the corresponding lysate from 
Step 9 (Fig. 6b). 
ii. Incubate in a 37˚C water bath for an additional 30 min. 
CRITICAL STEP Resuspending the PEG pellet is difficult and will take 
approximately 5 min per pellet. Be sure to collect the entire pellet, some of 
which sticks to the walls and beveled edges of 250 ml tubes. Do not use a 
serological pipet to resuspend the pellet, which can become lodged within the 
barrel of the pipet. 
CRITICAL STEP Collect a 30 µl sample from the PEG pellet resuspension for 
troubleshooting.  
PAUSE POINT Store the lysate at 4˚C overnight. Alternatively, use a dry ice-
ethanol bath to freeze the lysate; store at -20˚C for up to 1 week.  
 
AAV purification 
TIMING 1 d 
CRITICAL One iodixanol density gradient is sufficient to purify virus from up to 10, 150 mm 
dishes. If more than 10 dishes per prep are used, divide the lysate into more than one gradient. 
The AAV purification steps are most easily learned by visualization; refer to Figure 7 and 
Videos 1-2 for details.  
  
15. Determine the number of gradients needed and prepare the iodixanol density step 
solutions (see REAGENT SETUP and Supplementary Table 3). Set the OptiSeal tubes 
in the rack provided in the OptiSeal tube kit; alternatively, use the long edge of a 50 ml 
tube Styrofoam rack.  
CRITICAL STEP Check OptiSeal tubes for defects; do not use tubes with dents.  
 
16. Pour the density gradients (Fig. 7a-b and Video 1, 0:00-1:45). Each gradient is composed 
of the following density steps: 6 ml of 15% iodixanol, 6 ml of 25% iodixanol, 5 ml of 40% 
iodixanol, and 5 ml of 60% iodixanol (Supplementary Table 3). Note that only Corning 
brand 2 ml serological pipets consistently fit into OptiSeal tubes; alternatively, attach a 
small piece of clear tubing (6 mm) (e.g., Tygon Tubing) to a 5 ml pipet to pour the 
gradients. Begin by pipetting 6 ml (measure to the 3 ml mark twice if using 2 ml pipets) of 
15% iodixanol into each tube. Next, add 6 ml of 25% iodixanol under the 15% step by 
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lightly touching the pipet tip to the bottom of the tube and slowly releasing the solution 
(Fig. 7a). Continue adding layers of increasing density under the previous layer.  
CRITICAL STEP Use a pipetting device with precise control. When loading the 25%, 40%, 
and 60% steps, stop releasing the solution and slowly remove the pipet once the iodixanol 
is approximately 5 mm from the tip of the pipet (Video 1, 0:42-0:58 and 1:20-1:25). This 
will prevent an air bubble from disturbing the gradient. The remaining iodixanol will be 
released when the pipet is removed from the tube. The gradients should have a sharp 
delineation between steps (Fig. 7b).  
TROUBLESHOOTING 
 
17. Centrifuge the lysate from Step 14 at 2,000 x g for 10 min at RT. Centrifugation will result 
in the formation of a pellet (Fig. 6b). 
 
18. Use a 2 ml serological pipet to load the supernatant (i.e., the clarified lysate) 
(approximately 6-7 ml total) from Step 17 above the 15% iodixanol step (Fig. 7c and Video 
1, 1:46-2:22). Touch the pipet tip to the surface of the 15% step and slowly release the 
lysate such that a layer forms on top. 
CRITICAL STEP Do not allow the lysate to drip from the pipet tip onto the 15% step; this 
will cause the lysate to mix with the gradient.  
CRITICAL STEP The pellet may be soft, making it difficult to retrieve all of the 
supernatant. After loading 6-7 ml of lysate above the 15% step, spin the lysate for an 
additional 15 min at 3,000 x g; load the remaining supernatant onto the lysate layer. 
Discard the pellet.   
CRITICAL STEP Collect a 30 µl sample from the lysate for troubleshooting.  
 
19. Fill each tube up to the neck with SAN digestion buffer. Insert a black cap (Fig. 7d) and 
place a spacer on top (Fig. 7e). Caps and spacers are provided with the OptiSeal tubes 
and in the OptiSeal tube kit, respectively. 
 
20. Weigh the tubes with caps and spacers on. Balance the tubes to within 5-10 mg of each 
other using SAN digestion buffer. Be sure to adjust the tube weight in the biosafety cabinet; 
use the tube removal tool provided with the OptiSeal tube kit to remove the black cap and 
add the appropriate volume of SAN digestion buffer with a P20 or P200 pipet.  
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CAUTION Failure to balance tubes before ultracentrifugation could result in damaged 
equipment. 
 
21. Place the ultracentrifuge rotor in the biosafety cabinet. Load the tubes and fasten the lid.  
CAUTION To prevent damage to the rotor, set it on a paper towel so that the overspeed 
disk at the bottom is not scratched. 
 
22. Carefully transfer the rotor to the ultracentrifuge. Spin the Type 70 Ti rotor at 350,000 x g 
(58,400 rpm) for 2 h and 25 min at 18˚C with slow acceleration (#3) and deceleration 
(#9) profiles. Alternatively, a Type 60 Ti rotor can be used at 358,000 x g (59,000 rpm). 
CAUTION Always follow the manufacturer’s instructions while operating an 
ultracentrifuge.  
 
23. During ultracentrifugation, gather the supplies and equipment for Steps 24-27. Assemble 
the clamp setup and collect one of each of the following per gradient: Amicon Ultra-15 
centrifugal filter device, 5 ml syringe, 10 ml syringe, 0.22 µm syringe filter unit, and a 16 
G needle. 
 
24. After the spin is complete, bring the rotor inside the biosafety cabinet and remove the lid. 
Use the spacer removal tool provided with the OptiSeal tube kit to remove the spacer 
from the first tube. Next, use the tube removal tool to grip the tube neck. Slowly remove 
the tube from the rotor and secure it into the clamp setup above a 500 ml or 1 L beaker 
containing 10% bleach (Fig. 7f). Clean the side of the tube with 70% ethanol. 
CAUTION The black cap may become dislodged from the tube during removal, 
increasing the likelihood of a spill. Try replacing the cap before removing the tube from 
the rotor. Otherwise, replace the cap once the tube is secured in the clamp setup. 
 
25. Prepare the supplies for Steps 26 and 27. First, rinse the filtration membrane in the 
Amicon centrifugal filter device by adding 15 ml of DPBS to the top chamber and 
centrifuging at 3,000 x g for 3 min at RT; discard the flow-through. Next, remove and 
save the plunger from a 10 ml syringe. Attach a 0.22 µm syringe filter unit to the syringe 
barrel and place it on top of a rinsed Amicon filter device. Add 10 ml of DPBS to the 
barrel and allow the solution to begin dripping through the syringe filter unit and into the 
filter device (Fig. 7f). Lastly, attach a 16 G needle to a 5 ml syringe. 
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26. Collect the virus from the 40/60% interface and 40% step8,9 (Fig. 7g and Video 2, 0:00-
1:30). Hold the top of the OptiSeal tube with the non-dominant hand; use the dominant 
hand to hold the needle/syringe. Use a forward twisting motion to insert the needle 
approximately 4 mm below the 40/60% interface (i.e., where the tube just starts to 
curve). Use the tube removal tool in the non-dominant hand to remove the black cap 
from the tube to provide a hole for air entry. With the bevel up, use the needle/syringe to 
collect 4.0-4.5 ml of virus/iodixanol from the 40/60% interface and 40% step. Do not 
collect any of the visible protein band at the 25/40% interface; as this interface is 
approached, rotate the needle bevel down and continue collecting from the 40% step. 
Firmly replace the black cap before removing the needle from the tube.  
CAUTION Keep hands out of the path of the needle to prevent accidental exposure to 
AAVs. Failure to firmly replace the black cap before removing the needle will cause the 
AAV-contaminated solution to flow out of the needle hole in the tube and potentially onto 
and out of the biosafety cabinet. Perform this step over a large beaker of 10% bleach 
(Fig. 7f).  
CRITICAL STEP The virus should concentrate at the 40/60% interface and within the 
40% step9. There will not be a visible virus band, but the phenol red in the 25% and 60% 
steps helps to better define the 40% cushion. 
CRITICAL STEP Practice puncturing an empty OptiSeal tube with a needle before 
attempting to collect virus from the density gradient.  
CRITICAL STEP Collect a 30 µl sample from the virus/iodixanol for troubleshooting.  
TROUBLESHOOTING 
 
27. Add the 4.0-4.5 ml of virus/iodixanol to the syringe barrel containing 10 ml of DPBS 
(prepared in Step 25) (Fig. 7h and Video 2, 1:31-2:06). Layer the virus below the DPBS 
by placing the needle near the bottom of the barrel and pressing on the plunger. Insert the 
10 ml syringe plunger into the barrel and push the virus/DPBS mixture through the syringe 
filter unit and into the Amicon filter device (Video 2, 2:07-2:35). Mix well using a P1000 
pipet.  
CRITICAL STEP This filtration step reduces the likelihood of clogging the filtration 
membrane in the Amicon filter device. The virus/iodixanol mixture will be difficult to push 
through the syringe filter unit; DPBS will be easy to push through as it washes the filter. 
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CRITICAL STEP AAVs adhere to hydrophobic surfaces including plastics. Pluronic F-68 
is a non-ionic surfactant that may reduce virus loss associated with sticking to plastics. 
Optional: Include 0.001% Pluronic F-68 in DPBS for Steps 27-30. 
 
28. Centrifuge the virus/DPBS mixture at 3,000 x g for 5-8 min, or until the volume of the 
solution remaining in the top chamber of the Amicon filter device is 500-1500 µl (>10X 
concentrated). 
CRITICAL STEP This step may take longer because iodixanol initially slows down the 
passage of the solution through the filtration membrane. 
 
29. Discard the flow-through for bleaching. Add 14 ml of DPBS to the virus in the top 
chamber and use a P1000 pipet to mix. 
 
30. Centrifuge the virus/DPBS mixture as in Step 28. Wash the virus 2 more times for a total 
of 4 buffer exchanges. During the last spin, retain 500-1000 µl of solution in the top 
chamber. 
CRITICAL STEP The third and fourth washes may only require a 2-3 min spin until the 
volume of the solution remaining in the top chamber is 500-1000 µl. 
 
31. Filter sterilize the virus. Attach a 0.22 µm syringe filter unit to a 5 ml syringe. Pre-wet the 
filter with 200 µl of DPBS and discard the flow-through before filtering the virus. Use a 
P200 pipet to transfer the virus from the top chamber of the Amicon filter device directly 
into the syringe barrel. Push the virus through the filter and into a 1.6 ml screw-cap vial; 
store at 4˚C. 
PAUSE POINT Store the purified virus under sterile conditions at 4˚C for up to 6 months. 
CRITICAL STEP Amicon filter devices are not sterile; the virus should therefore be filter 
sterilized before storage. Virus stocks may be difficult to push through the filter; press 
the filter down onto the vial and push the plunger slowly to prevent liquid from spraying 
out of the syringe and onto or out of the biosafety cabinet. 
CRITICAL STEP The screw-cap vials are not low protein binding; however, they help 
prevent the formation of aerosols when opening and closing the tubes. We store AAVs in 
screw-cap vials at 4˚C and typically use them within 3 months, during which time we 
have not noticed a significant decrease in titers or transduction efficiency in vivo. We 
have not rigorously tested the effects of long-term storage at -20˚C or -80˚C. 
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TROUBLESHOOTING 
 
AAV titration 
TIMING 1 d 
CRITICAL The AAV titration procedure below is adapted from ref. 10. Each virus sample is 
prepared in triplicate in separate 1.5 ml DNA/RNA LoBind microcentrifuge tubes and later 
loaded into a 96-well plate for qPCR. All solutions must be accurately pipetted and thoroughly 
mixed; qPCR is highly sensitive to small changes in DNA concentration.       
 
32. Prepare a plan for the PCR plate setup. Allocate the first 24 wells (A1-B12) for the DNA 
standards such that standard #1 occupies wells A1-A3, standard #2 occupies wells A4-
A6, and so on. Use the remaining wells for the virus samples such that the first virus 
sample occupies wells C1-C3, the second sample occupies wells C4-C6, and so on. 
CRITICAL Include water as a negative control and a virus sample with a known 
concentration as a positive control; prepare the positive control with the virus samples in 
Steps 33-40. 
 
33. Use DNAse I to digest DNA that was not packaged into the viral capsid. Prepare DNAse 
I + DNAse digestion buffer and aliquot 100 µl to each 1.5 ml tube. Vortex each virus for 
1-2 s to mix and pipet 2 µl into each of three tubes. Briefly vortex and spin down; 
incubate in a 37˚C water bath for 1 h. 
CRITICAL Prepare each virus sample in triplicate. 
 
34. Inactivate the DNAse. Add 5 µl of EDTA to each tube; briefly vortex to mix, spin down, 
and incubate in a 70˚C dry bath for 10 min. 
CRITICAL STEP DNAse must be inactivated or else it will degrade the viral genome 
when it is released from the viral capsid in Step 35.     
 
35. Use proteinase K to digest the viral capsid and release the viral genome. Prepare 
proteinase K + proteinase K solution and add 120 µl to each tube. Briefly vortex and spin 
down; incubate in a 50˚C dry bath for 2 h. 
PAUSE POINT Samples may be incubated at 50˚C overnight. 
 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/246405doi: bioRxiv preprint first posted online Jan. 11, 2018; 
31 
 
36. During the last 20 min of the proteinase K digestion, prepare the DNA standard dilutions 
and use the Qubit assay to measure the concentration (ng/µl) of the DNA standard 
stock. 
CRITICAL STEP The concentration of the standard stock solution will be used to 
generate the standard curve after qPCR (Supplementary Table 4, cell B9).  
 
37. Inactivate the proteinase K. Incubate the tubes in a 95˚C dry bath for 10 min. 
CAUTION Tube caps may pop open unexpectedly; use safety glasses while removing 
the tubes from the 95˚C dry bath. 
CRITICAL STEP Proteinase K must be inactivated or else it will digest DNA polymerase 
during qPCR.  
 
38.  Allow the tubes to cool. Briefly vortex each sample and add 3 µl to a new tube 
containing 897 µl of Ultrapure water (a 1:300 dilution). Briefly vortex the diluted samples. 
 
39. Prepare the qPCR master mix. 
 
40. Load the PCR plate based on the experimental plan from Step 32. First, pipet 23 µl of 
qPCR master mix into each designated well. Next, pipet 2 µl of each standard into wells 
A1-B12. Lastly, pipet 2 µl of each diluted sample from Step 38 into wells C1 and onward. 
Seal the plate with sealing film and briefly spin down in a plate spinner.  
 
41. Place the PCR plate into the qPCR machine. Use the following cycling parameters: 
Step 1. 95˚C 10 min 
Step 2. 95˚C 15 s 
Step 3. 60˚C 20 s 
Step 4. 60˚C 40 s 
Repeat Steps 2-4 40X. 
 
42. When the qPCR run is complete, export the cycle threshold (Ct) values to an Excel file. 
Use Supplementary Table 4 to generate a standard curve and calculate the titer (vg/ml) 
(cell G27) of each virus; calculate per plate production (vg/dish) (cell K27) to assess 
production efficiency. 
TROUBLESHOOTING 
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Intravenous (retro-orbital) injection 
TIMING 2-5 min per mouse, excluding set-up and clean-up time 
CAUTION Follow appropriate institutional and governmental guidelines and regulations for 
husbandry and handling of laboratory animals. Note that, compared to tail vein injections, retro-
orbital injections require less technical expertise and may cause less distress in rodents11; 
however, tail vein injections appear to result in similar AAV distribution17. 
CRITICAL When possible, verify viral transduction and transgene expression in vitro before 
systemic administration. Note that co-injecting AAVs with other substances (e.g., dyes) could 
affect infectivity in vivo and should be tested independently. 
CRITICAL Re-titer viruses before injection if more than 1 month has passed since titration; this 
will ensure that animals are administered the most accurate dose possible. 
 
43. Determine the dose of virus to administer per mouse (see Experimental design section 
for recommendations). Divide the dose (vg) by the titer (vg/ml) (Supplementary Table 
4, cell G27) to calculate the volume of virus needed to inject one mouse. In a screw-cap 
vial, prepare a master mix of virus based on the number of animals to be injected; briefly 
vortex each virus and master mix 1-2 s before use. Transport the virus on ice once it is 
ready for injection.  
CAUTION Do not inject more than 10% of the mouse blood volume, which corresponds 
to 150 µl for a 25 g mouse. 
CRITICAL STEP Depending on the user, it is easiest to inject 40-80 µl/mouse. If less 
than 40 µl/mouse is required, use DPBS or saline to dilute the virus such that a larger 
volume is injected. If more than 80 µl/mouse is required, it may be more convenient to 
re-concentrate the virus or perform two separate injections; follow institutional guidelines 
for multiple eye injections. Virus will be lost in the event of an unsuccessful injection; 
therefore, prepare more master mix than is required. 
CRITICAL STEP To reduce the chance of contaminating the virus stock, avoid using the 
original virus stock; only bring an aliquot of what is needed for the injection(s).  
TROUBLESHOOTING 
 
44. Assemble the anesthesia system53 inside the biosafety cabinet. 
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45. Remove the mouse from its cage and place it in the induction chamber. Anesthetize the 
mouse with 1-5% isoflurane. 
CAUTION Isoflurane must be handled according to federal, state, and local regulations.    
 
46. While the mouse is being induced, load an insulin syringe with virus. Remove the dead 
space in the syringe barrel by gently ejecting the virus back into the tube such that air 
bubbles are expelled. Load the syringe again and repeat the procedure until no bubbles 
remain in the barrel. 
CAUTION Introducing air into the vascular system can be fatal. 
CRITICAL STEP Introducing air into the virus may cause protein denaturation; perform 
this step gently and only until no bubbles remain in the syringe barrel.  
 
47. Remove the anesthetized mouse from the induction chamber. Place the animal in a 
prone position on a small stack of paper towels. Position the mouse such that its head is 
situated on the same side as the operator’s dominant hand. Place the nose cone on the 
mouse to maintain anesthesia. 
 
48. Use the index finger and thumb on the non-dominant hand to draw back the skin above 
and below the eye, causing the eye to slightly protrude from the socket11. With the 
dominant hand, insert the needle, bevel down, at a 30-45˚ angle into the medial canthus 
and through the conjunctival membrane. The needle should be positioned behind the 
globe of the eye in the retro-orbital sinus. Slowly release the virus into the sinus and 
gently remove the needle.  
CAUTION Assess anesthetic depth by loss of pedal reflex (via toe pinch) before 
inserting the needle into the retro-orbital sinus. Any movement of the eye or skin when 
the needle is inserted indicates incorrect needle placement. Keep hands out of the path 
of the needle to prevent accidental exposure to AAVs. Do not recap needles; discard 
into an approved biohazardous sharps container immediately after use.  
CRITICAL STEP No liquid should leak out of the eye after viral delivery; likewise, little to 
no bleeding should be observed. 
TROUBLESHOOTING  
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49. Following viral injection, apply mild pressure to the eyelid. Apply 1-2 drops of proparacaine 
to the corneal surface to provide local analgesia. After recovery from anesthesia, place 
the mouse in a clean cage.  
CAUTION Monitor the eye daily after injection for 2 d, or according to institutional 
guidelines. 
 
Evaluation of transgene expression 
TIMING Variable; see Experimental design section 
CAUTION Follow appropriate institutional and governmental guidelines and regulations for 
husbandry and handling of laboratory animals. 
 
50. Euthanize animals after sufficient time has passed for viral transduction and protein 
expression (see Experimental design section for recommendations). Assess fluorescent 
protein labeling (if applicable) in the tissue(s) of interest using standard histological 
methods for thin slices or tissue clearing (e.g., CLARITY24 or ScaleSQ25) for thick tissue 
samples. Ensure that the chosen clearing protocol is compatible with the fluorescent 
protein(s) under investigation (see Experimental design and Anticipated Results sections 
for details). For experiments without fluorescent labels, evaluate transgene expression 
using molecular (e.g., qPCR or Western blot), histological (e.g. with antibodies, small 
molecule dyes, or molecular probes) or functional (e.g., optical imaging) methods relevant 
to the experimental aims. 
TROUBLESHOOTING 
------------------------------------------------------------------------------------------------------------------------------- 
TIMING 
Refer to Figure 6a for a timeline of the procedure.  
Steps 1-3, Triple transient transfection of HEK293T cells: 1-2 h 
Steps 4-14, AAV harvest: 5 d  
Steps 15-31, AAV purification: 1 d 
Steps 32-42, AAV titration: 1 d 
Steps 43-49, Intravenous (retro-orbital) injection: 2-5 min per mouse, excluding set-up and 
clean-up time 
Step 50, Evaluation of transgene expression: Variable 
------------------------------------------------------------------------------------------------------------------------------- 
ANTICIPATED RESULTS 
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AAV production 
For capsids that package well (i.e., AAV-PHP.B, AAV-PHP.eB, and AAV-PHP.S), the AAV 
production protocol typically yields over 1 x 1012 vg per 150 mm dish2,3 (Supplementary Table 
1). Production efficiency can be determined for each virus in Step 42 (Supplementary Table 4, 
cell K27). Note that yields may vary from prep to prep and genome to genome. Users can 
gauge production efficiency for each experiment by running a positive control (e.g., pAAV-CAG-
eYFP (Addgene ID 104055)). 
 
Evaluation of transgene expression 
For most applications, users can expect to assess transduced cells beginning 2 or more weeks 
after intravenous injection (see Experimental design section for details). The chosen method for 
evaluating transgene expression will vary from user to user and may involve molecular, 
histological, and/or functional approaches (Step 50). We typically use fluorescent reporters to 
assess gene expression in thick (≥100 µm), cleared tissue samples; below, we discuss 
expected results for applications presented here (Figs. 2-4) and in our previous work2,3.  
Commonly used reporters like GFP, eYFP, and tdTomato show strong fluorescent 
labeling in PACT- and PARS-cleared tissues, enabling whole-organ and thick-tissue imaging of 
transgene expression3,22,24. Most markers, including mTurquoise2, mNeonGreen, and mRuby2, 
can also be detected after mounting labeled tissues in optical clearing reagents like RIMS24 
(Fig. 3b), ScaleSQ25 (Figs. 3a, 3c-d, and 4b-d), and Prolong Diamond Antifade (Thermo Fisher 
Scientific, cat. no. P36965)2. Depending on the rAAV genome, fluorescent proteins may be 
localized to distinct cellular compartments including the nucleus (via NLS) (Fig. 2), cytosol 
(Figs. 3a-c and 4b), and cell membrane (via farnesylation55 or fusion to a membrane protein like 
ChR2) (Figs. 3d and 4d). Some fluorescent proteins are susceptible to photobleaching. For 
example, mRuby2 may bleach over extended imaging sessions; tdTomato exhibits similar 
spectral properties and may be a more suitable alternative given its photostability56. Note that 
autofluorescent lipofuscin accumulates in aging postmitotic tissues (e.g., the brain and heart)57 
and may interfere with examining transduced cells; either reduce autofluorescence using 
histological methods24 or, if possible, inject younger adults (≤8 weeks old) and determine the 
minimum time required for transgene expression.  
Regardless of the approach used to evaluate gene expression, cell type-specific 
promoters should be verified at this stage in the protocol; we typically assess cell morphology 
and/or use antibody staining to confirm specificity (Fig. 2b-c). 
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Conclusion 
In summary, we present a comprehensive protocol for the production and administration of 
AAV-PHP viruses, which is also applicable to the production and systemic delivery of other AAV 
serotypes. We have validated the ability of AAV-PHP variants to provide efficient and 
noninvasive gene delivery to specific cell populations throughout the body. Together, this AAV 
toolbox equips users with the resources needed for a variety of applications across the 
biomedical sciences.   
  
FIGURE LEGENDS 
Figure 1. Overview of the protocol. The procedure comprises three main stages: AAV 
production (Steps 1-42), intravenous delivery (Steps 43-49), and evaluation of transgene 
expression (Step 50). The pAAV plasmid contains the rAAV genome (e.g., containing a 
fluorescent reporter, shown in green) (Fig. 5 and Table 1), which is packaged into an AAV-PHP 
capsid via triple transient transfection. Systemic administration of AAV-PHP viruses is achieved 
via retro-orbital injection into wild-type or transgenic mice; transgene expression is evaluated 
after adequate time has passed for viral transduction and protein expression. AAV-PHP viruses 
target cells in the CNS (e.g., in the brain and spinal cord) or PNS and visceral organs (e.g., in 
the heart and gut). Filled green circles represent transduced cells. For illustrative purposes, we 
use fluorescent labeling as an example of how to assess transgene expression; however, 
assessment can take on other forms (see Experimental design section for details). See Figure 
6a for a timeline of the procedure. 
 
Figure 2. AAV-PHP.eB targets diverse cell types throughout the brain. We used AAV-
PHP.eB to package single-stranded (ss) rAAV genomes that express nuclear localized (NLS) 
fluorescent reporters (XFP) from cell type-specific promoters. Genomes containing the hSyn1, 
MBP, or GFAP promoters were used to target neurons, oligodendrocytes, or astrocytes, 
respectively. Viruses were co-delivered via retro-orbital injection to a 7 week old wild-type 
mouse at 3 x 1011 vg/virus; gene expression in the brain was evaluated 4 weeks later. (a) 
Coronal image of the brain; inset shows zoomed-in view of the hippocampus. XFPs were 
mNeonGreen (mNG), tdTomato (tdT), or mTurquoise2 (mTurq2). (b and c) Antibody staining 
can be used to determine the specificity and efficiency of cell type-specific promoters. (b) NeuN, 
Olig2, and S100 mark neurons, oligodendrocyte lineage cells, and a population of glia that 
consists mostly of astrocytes, respectively. Images from the cortex and thalamus are shown. All 
brain slices were mounted in Prolong Diamond Antifade; images were acquired using confocal 
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microscopy and are presented as maximum intensity projections. Refer to Table 1 for details 
regarding rAAV genomes. (c) “Specificity” or “efficiency” are defined as the ratio of XFP 
labeled/antibody labeled cells to the total number of XFP or antibody labeled cells, respectively. 
For image processing, median filtering and background subtraction using morphological 
opening were first applied to each image to reduce noise and correct imbalanced illumination. 
Each nucleus expressing XFPs and labeled with antibodies was then segmented by applying a 
Laplacian of Gaussian filter to the pre-processed images. We considered cells that are both 
expressing XFPs and labeled with antibodies if the nearest center-to-center distance between 
blobs (nuclei or cell bodies) in two channels was less than 7 µm (half of the cell body size). 
Experiments on vertebrates conformed to all relevant governmental and institutional regulations 
and were approved by the Institutional Animal Care and Use Committee (IACUC) and the Office 
of Laboratory Animal Resources at the California Institute of Technology.  
 
Figure 3. AAV-PHP.S transduces neurons throughout the PNS. We used AAV-PHP.S to 
package single-stranded (ss) rAAV genomes that express fluorescent reporters from either 
neuron-specific (e.g., hSyn1 and TH) or ubiquitous promoters (e.g., CAG). Viruses were 
delivered via retro-orbital injection to 6-8 week old wild-type or Cre transgenic mice and 
transgene expression was evaluated 2-3 weeks later. (a) ssAAV-PHP.S:hSyn1-mNeonGreen 
and ssAAV-PHP.S:CAG-DIO-mRuby2 were co-injected into a TH-IRES-Cre mouse at 1 x 1012 
vg/virus. Native mNeonGreen and mRuby2 fluorescence were assessed 2 weeks later via wide-
field (left) or confocal fluorescence microscopy (right). Images are from the second to sixth 
thoracic (T2-T6) (left) and eighth cervical to second thoracic (C8-T2) (right) paravertebral 
ganglia, which provide sympathetic innervation to thoracic organs including the heart. Arrows 
denote mNeonGreen-positive nerve fibers. (b) ssAAV-PHP.S:CAG-DIO-eYFP was injected into 
a TRPV1-IRES-Cre mouse at 1 x 1012 vg; gene expression in a nodose ganglion was evaluated 
3 weeks later. (c) A mixture of 3 separate viruses (ssAAV-PHP.S:CAG-DIO-XFPs) were injected 
into a TRPV1-IRES-Cre mouse at 1 x 1012 vg/virus; gene expression in a dorsal root ganglion 
was evaluated 2 weeks later. XFPs were mTurquoise2, mNeonGreen, or mRuby2. (d) ssAAV-
PHP.S:rTH-GFP and ssAAV-PHP.S:hSyn1-tdTomato-f (farnesylated) were co-injected into a 
C57BL/6J mouse at 5 x 1011 vg/virus; gene expression in the duodenum was assessed 22 d 
later. The image stack includes both the myenteric and submucosal plexus. Inset shows 
zoomed-in view of ganglia containing TH+ cell bodies; tdTomato-f labels both thick nerve 
bundles and individual fibers. Whole-mount tissues were optically cleared using either 
ScaleSQ25 (a (right), c, and d) or RIMS24 (b) and imaged using confocal microscopy, unless 
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stated otherwise; all confocal images are presented as maximum intensity projections. Refer to 
Table 1 for details regarding rAAV genomes. Experiments on vertebrates conformed to all 
relevant governmental and institutional regulations and were approved by the Institutional 
Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the 
California Institute of Technology.   
 
Figure 4. AAV-PHP.S for mapping the anatomy and physiology of the heart. AAV-PHP.S 
viruses were delivered via retro-orbital injection to 6-8 week old wild-type or Cre transgenic 
mice. (a) AAV-PHP.S transduces the heart more efficiently than the current standard, AAV9. 
ssAAV9:CAG-NLS-GFP or ssAAV-PHP.S:CAG-NLS-GFP were injected into C57BL/6J mice at 
1 x 1012 vg. Native GFP fluorescence was assessed in whole mount hearts 4 weeks later via 
wide-field fluorescence microscopy (t7=8.449 and p<0.0001, unpaired t test). For AAV9 and 
AAV-PHP.S, n=5 and 4, respectively. (b) A mixture of 3 viruses (ssAAV-PHP.S:CAG-XFPs) 
were injected into a C57BL/6J mouse at 3.3 x 1011 vg/virus; gene expression in cardiac muscle 
was evaluated 11 d later, allowing individual cardiomyocytes to be easily distinguished from one 
another. XFPs were mTurquoise2, mNeonGreen, or mRuby2. (c) A mixture of 3 viruses 
(ssAAV-PHP.S:CAG-DIO-XFPs) were injected into a TRPV1-IRES-Cre mouse at 1 x 1012 
vg/virus; gene expression in TRPV1-expressing cardiac nerves was evaluated 2 weeks later. (d) 
ssAAV-PHP.S:Ef1ɑ-DIO-ChR2-eYFP was injected into a ChAT-IRES-Cre mouse at 1 x 1012 vg; 
gene expression in a cardiac ganglion was evaluated 3 weeks later (left). Ex vivo intracellular 
recordings were performed after 5 weeks of expression. DIC image (middle) shows the optical 
fiber for light delivery and electrode for concurrent intracellular recordings; inset shows a higher 
magnification image of a selected cell (asterisk). Cholinergic neurons generated action 
potentials in response to 473 nm light pulses (5 Hz, 20 ms) (right). Whole-mount tissues were 
optically cleared using ScaleSQ25 (b, c, and d (left)) and imaged using confocal microscopy, 
unless stated otherwise; all confocal images are presented as maximum intensity projections. 
Refer to Table 1 for details regarding rAAV genomes. Experiments on vertebrates conformed to 
all relevant governmental and institutional regulations and were approved by the Institutional 
Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the 
California Institute of Technology.  
 
Figure 5. A modular AAV toolbox for cell type-specific gene expression. The rAAV 
genome, contained in a pAAV plasmid (not shown), consists of an expression cassette flanked 
by two 145 bp inverted terminal repeats (ITRs); the entire genome, including the ITRs, cannot 
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exceed 5 kb. The promoters, transgenes, localization signals, and recombination schemes are 
interchangeable. Gene regulatory elements, such as promoters and microRNA (miRNA) binding 
sites, determine the strength and specificity of transgene expression16. Transgenes may be 
constitutively expressed or flanked by recombination sites for flippase (Flp)- or Cre recombinase 
(Cre)-dependent expression. In the latter approach, the transgene remains in the double-floxed 
inverted orientation (DIO); Cre- or Flp-mediated inversion of the transgene enables cell type-
specific expression in transgenic mice (Fig. 3a-c and 4c-d). Localization sequences further 
restrict gene expression to distinct cellular compartments such as the nucleus (via one or more 
nuclear localization signals (NLS)) (Fig. 2), cytosol (via a nuclear exclusion signal (NES)58), or 
cell membrane (via farnesylation55, the CD4-259 transmembrane (TM) targeting domain, or 
PDZ60 protein-protein interaction domains) (Fig. 3d). Note that the 3’ UTR contains the 
woodchuck hepatitis posttranscriptional regulatory element (WPRE) (609 bp) and a 
polyadenylation signal (e.g., the human growth hormone (hGH) polyA) (479 bp) (not shown), 
both of which enhance transgene expression16. Use sequence editing and annotation software 
to determine the unique attributes of the rAAV genome. In Table 1, we list genomes used here 
and in our previous work2,3; see also Addgene’s plasmid repository for pAAVs that may be 
suitable for different applications. DREADDs = Designer Receptors Exclusively Activated by 
Designed Drugs; CRISPR = Clustered Regularly Interspaced Short Palindromic Repeats; 
shRNA = short hairpin RNA. 
 
Figure 6. Timeline and AAV harvest procedure. (a) Timeline of the procedure. The entire 
protocol spans 8 d, excluding pause points on days 5 (Steps 11 and 14), 6 (Step 31), and 7 
(Step 35) and the time required to evaluate transgene expression (Step 50). Days 1-7 (Steps 1-
42) comprise the AAV production stage (Fig. 1). (b) Schematic of the AAV harvest procedure 
with images corresponding to indicated steps. Note that this iodixanol-based purification 
protocol does not eliminate empty capsids (i.e., capsids that fail to package a rAAV genome), as 
determined by negative staining transmission electron microscopy; empty particles are 
characterized by an electron-dense core. Grayed arrows and text denote steps where the 
supernatant and pellet can be bleached and discarded (Steps 13 and 18). 
 
Figure 7. AAV purification procedure. (a-b) In Step 16, pipet the iodixanol density gradients 
(Video 1, 0:00-1:45). (a) Layer the 25% iodixanol underneath the 15% step (Video 1, 0:12-
1:28). (b) Add layers of increasing density under the previous layer (Video 1, 1:29-1:45); the 
gradients should have a sharp delineation between steps. (c) In Step 18, load the supernatant 
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(Sup.) from Step 17 (Fig. 6b) above the 15% step (Video 1, 1:46-2:22). (d-e) In Step 19, fill 
each tube up to the neck with SAN digestion buffer and insert a black cap (d); place a spacer on 
top before weighing the tubes (e). (f) After ultracentrifugation (Step 22), secure the tube into the 
clamp setup above a container of 10% bleach (Step 24). Allow 10 ml of DPBS to drip through 
the syringe filter unit into a rinsed Amicon filter device (Step 25). (g) In Step 26, collect the virus 
(Video 2, 0:00-1:30). Insert the needle approximately 4 mm below the 40/60% interface (i.e., 
where the tube just starts to curve) (Video 2, 0:06-0:21). Do not collect virus until the black cap 
is removed (asterisk) (Video 2, 0:22-0:30); do not collect from the protein layer at the 25/40% 
interface. (h) In Step 27, filter the virus/iodixanol (Video 2, 1:31-2:35). Inject the virus below the 
DPBS in the filter-attached syringe barrel (Video 2, 1:31-2:06) before pushing the virus/DPBS 
through the syringe filter unit and into the Amicon filter device.   
 
Table 1. AAV resources. A comprehensive list of plasmids used in this and related work2,3. The 
pHelper plasmid is available in Agilent's AAV helper-free kit (Agilent, cat. no. 240071). 
 
Table 2. Troubleshooting AAV production, purification, and administration protocols.  
 
Video 1. Steps 16 and 18 - Pouring the density gradient and loading the virus. 
 
Video 2. Steps 26-27 - Collecting the virus. 
 
Supplementary Table 1. AAV-PHP capsids for efficient transduction across specific 
organs and cell populations. Species, organs, and cell populations examined to-date following 
intravenous administration of AAV-PHP viruses. To restrict gene expression to distinct cell 
types, use rAAV genomes with cell type-specific gene regulatory elements and/or Cre- or Flp-
dependent recombination schemes (Figs. 2-4). Given the poor production efficiency of AAV-
PHP.A, we suggest using AAV-PHP.eB to target astrocytes. Use an astrocyte promoter, such 
as GFAP, to drive transgene expression (Fig. 2). 
 
Supplementary Table 2. Transfection calculator. This is an interactive calculator and 
provided as an Excel file (see Step 2 and REAGENT SETUP). 
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Supplementary Table 3. Pouring the iodixanol density step solutions. Determine the 
number of gradients needed and prepare the iodixanol density step solutions (see REAGENT 
SETUP for details). 
 
Supplementary Table 4. Titration calculator. This is an interactive calculator and provided as 
an Excel file (see Step 42 and REAGENT SETUP). 
 
ACKNOWLEDGEMENTS 
We thank M.S. Ladinsky for preparing transmission electron microscopy samples and for the 
image shown in Figure 6. This work was primarily supported by the National Institutes of Health 
(NIH) through grants to V.G.: Director's New Innovator DP2NS087949 and PECASE; SPARC 
OT2OD023848-01 (to V.G. and S.K.); National Institute on Aging R01AG047664; BRAIN 
U01NS090577; and the Defense Advanced Research Projects Agency (DARPA) Biological 
Technologies Office (BTO; to V.G. and B.E.D.). Additional funding included the NSF NeuroNex 
Technology Hub 1707316 (to V.G.), the Curci Foundation (to V.G.), the Beckman Institute (to 
V.G. and B.E.D.), and the Rosen Center (to V.G.) at Caltech. V.G. is a Heritage Principal 
Investigator supported by the Heritage Medical Research Institute. R.C.C. was supported by an 
American Heart Association Postdoctoral Fellowship 17POST33410404. C.M.C was funded by 
the National Institute on Aging F32AG054101 and P.S.R. was funded by the National Heart, 
Lung, and Blood Institute F31HL127974. 
 
AUTHOR CONTRIBUTIONS 
R.C.C. and V.G. wrote the manuscript with input from all coauthors. R.C.C., S.R.K., K.Y.C., 
C.M.C., M.J.J., P.S.R., J.D.T., S.K., B.E.D., and V.G. designed and performed experiments, 
analyzed the data, and prepared figures. V.G. supervised all aspects of the project. All authors 
edited and approved the manuscript.  
 
REFERENCES 
1 Samulski, R. J. & Muzyczka, N. in Annual Review of Virology, Vol 1 Vol. 1 Annual 
Review of Virology (ed L. W. Enquist)  427-451 (2014). 
 
2 Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central 
and peripheral nervous systems. Nature Neuroscience 20, 1172-+, doi:10.1038/nn.4593 
(2017). 
 
3 Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene 
transfer to the adult brain. Nature Biotechnology 34, 204-+, doi:10.1038/nbt.3440 (2016). 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/246405doi: bioRxiv preprint first posted online Jan. 11, 2018; 
42 
 
 
4 Reed, S. E., Staley, E. M., Mayginnes, J. P., Pintel, D. J. & Tullis, G. E. Transfection of 
mammalian cells using linear polyethylenimine is a simple and effective means of 
producing recombinant adeno-associated virus vectors. Journal of Virological Methods 
138, 85-98, doi:10.1016/j.jviromet.2006.07.024 (2006). 
 
5 Wright, J. F. Transient Transfection Methods for Clinical Adeno-Associated Viral Vector 
Production. Human Gene Therapy 20, 698-706, doi:10.1089/hum.2009.064 (2009). 
 
6 Xiao, X., Li, J. & Samulski, R. J. Production of high-titer recombinant adeno-associated 
virus vectors in the absence of helper adenovirus. Journal of Virology 72, 2224-2232 
(1998). 
 
7 Ayuso, E. et al. High AAV vector purity results in serotype- and tissue-independent 
enhancement of transduction efficiency. Gene Therapy 17, 503-510, 
doi:10.1038/gt.2009.157 (2010). 
 
8 Grieger, J. C., Choi, V. W. & Samulski, R. J. Production and characterization of adeno-
associated viral vectors. Nature Protocols 1, 1412-1428, doi:10.1038/nprot.2006.207 
(2006). 
 
9 Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel 
methods improves infectious titer and yield. Gene Therapy 6, 973-985, 
doi:10.1038/sj.gt.3300938 (1999). 
 
10 Gray, S. J. et al. Production of recombinant adeno-associated viral vectors and use in in 
vitro and in vivo administration. Current protocols in neuroscience Chapter 4, Unit 4.17, 
doi:10.1002/0471142301.ns0417s57 (2011). 
 
11 Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M. & Hoogstraten-Miller, S. Retro-
orbital injections in mice. Lab Animal 40, 155-160 (2011). 
 
12 Gray, S. J. et al. Preclinical Differences of Intravascular AAV9 Delivery to Neurons and 
Glia: A Comparative Study of Adult Mice and Nonhuman Primates. Molecular Therapy 
19, 1058-1069, doi:10.1038/mt.2011.72 (2011). 
 
13 Chakrabarty, P. et al. Capsid Serotype and Timing of Injection Determines AAV 
Transduction in the Neonatal Mice Brain. Plos One 8, doi:10.1371/journal.pone.0067680 
(2013). 
 
14 Maguire, C. A. et al. Mouse Gender Influences Brain Transduction by Intravascularly 
Administered AAV9. Molecular Therapy 21, 1469-1470 (2013). 
 
15 Chen, Y. H., Chang, M. & Davidson, B. L. Molecular signatures of disease brain 
endothelia provide new sites for CNS-directed enzyme therapy. Nature Medicine 15, 
1215-U1145, doi:10.1038/nm.2025 (2009). 
 
16 Powell, S. K., Rivera-Soto, R. & Gray, S. J. Viral Expression Cassette Elements to 
Enhance Transgene Target Specificity and Expression in Gene Therapy. Discovery 
Medicine 19, 49-57 (2015). 
 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/246405doi: bioRxiv preprint first posted online Jan. 11, 2018; 
43 
 
17 Morabito, G. et al. AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous 
System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy. 
Molecular Therapy, doi:http://dx.doi.org/10.1016/j.ymthe.2017.08.004 (2017). 
 
18 Jackson, K. L., Dayton, R. D., Deverman, B. E. & Klein, R. L. Better Targeting, Better 
Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-
PHP.B. Frontiers in Molecular Neuroscience 9, doi:10.3389/fnmol.2016.00116 (2016). 
 
19 Allen, W. E. et al. Global Representations of Goal-Directed Behavior in Distinct Cell 
Types of Mouse Neocortex. Neuron 94, 891-+, doi:10.1016/j.neuron.2017.04.017 
(2017). 
 
20 Hillier, D. et al. Causal evidence for retina-dependent and -independent visual motion 
computations in mouse cortex. Nature Neuroscience 20, 960-+, doi:10.1038/nn.4566 
(2017). 
 
21 Resendez, S. L. et al. Visualization of cortical, subcortical and deep brain neural circuit 
dynamics during naturalistic mammalian behavior with head-mounted microscopes and 
chronically implanted lenses. Nature Protocols 11, 566-597, doi:10.1038/nprot.2016.021 
(2016). 
 
22 Yang, B. et al. Single-Cell Phenotyping within Transparent Intact Tissue through Whole-
Body Clearing. Cell 158, 945-958, doi:10.1016/j.cell.2014.07.017 (2014). 
 
23 Richardson, D. S. & Lichtman, J. W. Clarifying Tissue Clearing. Cell 162, 246-257, 
doi:10.1016/j.cell.2015.06.067 (2015). 
 
24 Treweek, J. B. et al. Whole-body tissue stabilization and selective extractions via tissue-
hydrogel hybrids for high-resolution intact circuit mapping and phenotyping. Nature 
Protocols 10, 1860-1896, doi:10.1038/nprot.2015.122 (2015). 
 
25 Hama, H. et al. Sca/eS: an optical clearing palette for biological imaging. Nature 
Neuroscience 18, 1518-+, doi:10.1038/nn.4107 (2015). 
 
26 Choi, J. H. et al. Optimization of AAV expression cassettes to improve packaging 
capacity and transgene expression in neurons. Molecular Brain 7, doi:10.1186/1756-
6606-7-17 (2014). 
 
27 Paterna, J. C., Moccetti, T., Mura, A., Feldon, J. & Bueler, H. Influence of promoter and 
WHV post-transcriptional regulatory element on AAV-mediated transgene expression in 
the rat brain. Gene Therapy 7, 1304-1311, doi:10.1038/sj.gt.3301221 (2000). 
 
28 Xu, R. et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) 
brain-specific gene cassettes. Gene Therapy 8, 1323-1332, doi:10.1038/sj.gt.3301529 
(2001). 
 
29 de Leeuw, C. N. et al. rAAV-compatible MiniPromoters for restricted expression in the 
brain and eye. Molecular Brain 9, doi:10.1186/s13041-016-0232-4 (2016). 
 
30 Gray, S. J. et al. Optimizing Promoters for Recombinant Adeno-Associated Virus-
Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/246405doi: bioRxiv preprint first posted online Jan. 11, 2018; 
44 
 
Complementary Vectors. Human Gene Therapy 22, 1143-1153, 
doi:10.1089/hum.2010.245 (2011). 
 
31 Chamberlain, K., Riyad, J. M. & Weber, T. Expressing Transgenes That Exceed the 
Packaging Capacity of Adeno-Associated Virus Capsids. Human Gene Therapy 
Methods 27, 1-12, doi:10.1089/hgtb.2015.140 (2016). 
 
32 Broderick, J. A. & Zamore, P. D. MicroRNA therapeutics. Gene Therapy 18, 1104-1110, 
doi:10.1038/gt.2011.50 (2011). 
 
33 Xie, J. et al. MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-
restricted Transgene Expression. Molecular Therapy 19, 526-535, 
doi:10.1038/mt.2010.279 (2011). 
 
34 Nayak, S. & Herzog, R. W. Progress and prospects: immune responses to viral vectors. 
Gene Therapy 17, 295-304, doi:10.1038/gt.2009.148 (2010). 
 
35 Gao, K. et al. Empty virions in AAV8 vector preparations reduce transduction efficiency 
and may cause total viral particle dose-limiting side effects. Molecular Therapy-Methods 
& Clinical Development 1, doi:10.1038/mtm.2013.9 (2014). 
 
36 Mingozzi, F. & High, K. A. Immune responses to AAV vectors: overcoming barriers to 
successful gene therapy. Blood 122, 23-36, doi:10.1182/blood-2013-01-306647 (2013). 
 
37 Strobel, B., Miller, F. D., Rist, W. & Lamla, T. Comparative Analysis of Cesium Chloride- 
and Iodixanol-Based Purification of Recombinant Adeno-Associated Viral Vectors for 
Preclinical Applications. Human Gene Therapy Methods 26, 147-157, 
doi:10.1089/hgtb.2015.051 (2015). 
 
38 Lerner, T. N. et al. Intact-Brain Analyses Reveal Distinct Information Carried by SNc 
Dopamine Subcircuits. Cell 162, 635-647, doi:10.1016/j.cell.2015.07.014 (2015). 
 
39 Tervo, D. G. R. et al. A Designer AAV Variant Permits Efficient Retrograde Access to 
Projection Neurons. Neuron 92, 372-382, doi:10.1016/j.neuron.2016.09.021 (2016). 
 
40 Cai, D., Cohen, K. B., Luo, T., Lichtman, J. W. & Sanes, J. R. Improved tools for the 
Brainbow toolbox. Nature Methods 10, 540-+, doi:10.1038/nmeth.2450 (2013). 
 
41 Chang, R. B., Strochlic, D. E., Williams, E. K., Umans, B. D. & Liberles, S. D. Vagal 
Sensory Neuron Subtypes that Differentially Control Breathing. Cell 161, 622-633, 
doi:10.1016/j.cell.2015.03.022 (2015). 
 
42 Williams, E. K. et al. Sensory Neurons that Detect Stretch and Nutrients in the Digestive 
System. Cell 166, 209-221, doi:10.1016/j.cell.2016.05.011 (2016). 
 
43 Bruegmann, T. et al. Optogenetic control of heart muscle in vitro and in vivo. Nat 
Methods 7, 897-900, doi:10.1038/nmeth.1512 (2010). 
 
44 Guettier, J. M. et al. A chemical-genetic approach to study G protein regulation of beta 
cell function in vivo. Proceedings of the National Academy of Sciences of the United 
States of America 106, 19197-19202, doi:10.1073/pnas.0906593106 (2009). 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/246405doi: bioRxiv preprint first posted online Jan. 11, 2018; 
45 
 
 
45 Jain, S. et al. Chronic activation of a designer G(q)-coupled receptor improves beta cell 
function. The Journal of clinical investigation 123, 1750-1762, doi:10.1172/jci66432 
(2013). 
 
46 Li, J. H. et al. A novel experimental strategy to assess the metabolic effects of selective 
activation of a G(q)-coupled receptor in hepatocytes in vivo. Endocrinology 154, 3539-
3551, doi:10.1210/en.2012-2127 (2013). 
 
47 Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 
186-191, doi:10.1038/nature14299 (2015). 
 
48 Yang, Y. et al. A dual AAV system enables the Cas9-mediated correction of a metabolic 
liver disease in newborn mice. Nat Biotechnol 34, 334-338, doi:10.1038/nbt.3469 (2016). 
 
49 Senis, E. et al. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral 
(AAV) vector toolbox. Biotechnology journal 9, 1402-1412, doi:10.1002/biot.201400046 
(2014). 
 
50 Yang, Q. et al. AAV-based shRNA silencing of NF-kappaB ameliorates muscle 
pathologies in mdx mice. Gene Ther 19, 1196-1204, doi:10.1038/gt.2011.207 (2012). 
 
51 Petri, K. et al. Comparative next-generation sequencing of adeno-associated virus 
inverted terminal repeats. Biotechniques 56, 269-+, doi:10.2144/000114170 (2014). 
 
52 Masters, J. R. & Stacey, G. N. Changing medium and passaging cell lines. Nature 
Protocols 2, 2276-2284, doi:10.1038/nprot.2007.319 (2007). 
 
53 Database, J. S. E. in Lab Animal Research    (JoVE, Cambridge, MA, 2017). 
 
54 Lock, M. et al. Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-
Associated Viral Vectors at Scale. Human Gene Therapy 21, 1259-1271, 
doi:10.1089/hum.2010.055 (2010). 
 
55 Hancock, J. F., Cadwallader, K., Paterson, H. & Marshall, C. J. A CAAX OR A CAAL 
MOTIF AND A 2ND SIGNAL ARE SUFFICIENT FOR PLASMA-MEMBRANE 
TARGETING OF RAS PROTEINS. Embo Journal 10, 4033-4039 (1991). 
 
56 Day, R. N. & Davidson, M. W. The fluorescent protein palette: tools for cellular imaging. 
Chemical Society Reviews 38, 2887-2921, doi:10.1039/b901966a (2009). 
 
57 Gray, D. A. & Woulfe, J. Lipofuscin and aging: a matter of toxic waste. Science of aging 
knowledge environment : SAGE KE 2005, re1, doi:10.1126/sageke.2005.5.re1 (2005). 
 
58 Dana, H. et al. Sensitive red protein calcium indicators for imaging neural activity. eLife 
5, doi:10.7554/eLife.12727 (2016). 
 
59 Kim, J. et al. mGRASP enables mapping mammalian synaptic connectivity with light 
microscopy. Nature Methods 9, 96-U139, doi:10.1038/nmeth.1784 (2012). 
 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/246405doi: bioRxiv preprint first posted online Jan. 11, 2018; 
46 
 
60 Kim, E. J. & Sheng, M. PDZ domain proteins of synapses. Nat. Rev. Neurosci. 5, 771-
781, doi:10.1038/nrn1517 (2004). 
 
 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/246405doi: bioRxiv preprint first posted online Jan. 11, 2018; 
Figure 1. Overview of the protocol. The procedure comprises three main stages: AAV 
production (Steps 1-42), intravenous delivery (Steps 43-49), and evaluation of transgene 
expression (Step 50). The pAAV plasmid contains the rAAV genome (e.g., containing a 
fluorescent reporter, shown in green) (Fig. 5 and Table 1), which is packaged into an AAV-PHP 
capsid via triple transient transfection. Systemic administration of AAV-PHP viruses is achieved 
via retro-orbital injection into wild-type or transgenic mice; transgene expression is evaluated 
after adequate time has passed for viral transduction and protein expression. AAV-PHP viruses 
target cells in the CNS (e.g., in the brain and spinal cord) or PNS and visceral organs (e.g., in 
the heart and gut). Filled green circles represent transduced cells. For illustrative purposes, we 
use fluorescent labeling as an example of how to assess transgene expression; however, 
assessment can take on other forms (see Experimental design section for details). See Figure 
6a for a timeline of the procedure. 
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Figure 2. AAV-PHP.eB targets diverse cell types throughout the brain. We used AAV-PHP.eB to package single-stranded (ss) 
rAAV genomes that express nuclear localized (NLS) fluorescent reporters (XFP) from cell type-specific promoters. Genomes 
containing the hSyn1, MBP, or GFAP promoters were used to target neurons, oligodendrocytes, or astrocytes, respectively. Viruses 
were co-delivered via retro-orbital injection to a 7 week old wild-type mouse at 3 x 1011 vg/virus; gene expression in the brain was 
evaluated 4 weeks later. (a) Coronal image of the brain; inset shows zoomed-in view of the hippocampus. XFPs were mNeonGreen 
(mNG), tdTomato (tdT), or mTurquoise2 (mTurq2). (b and c) Antibody staining can be used to determine the specificity and efficiency 
of cell type-specific promoters. (b) NeuN, Olig2, and S100 mark neurons, oligodendrocyte lineage cells, and a population of glia that 
consists mostly of astrocytes, respectively. Images from the cortex and thalamus are shown. All brain slices were mounted in Prolong 
Diamond Antifade; images were acquired using confocal microscopy and are presented as maximum intensity projections. Refer to 
Table 1 for details regarding rAAV genomes. (c) “Specificity” or “efficiency” are defined as the ratio of XFP labeled/antibody labeled 
cells to the total number of XFP or antibody labeled cells, respectively. For image processing, median filtering and background 
subtraction using morphological opening were first applied to each image to reduce noise and correct imbalanced illumination. Each 
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nucleus expressing XFPs and labeled with antibodies was then segmented by applying a Laplacian of Gaussian filter to the pre-
processed images. We considered cells that are both expressing XFPs and labeled with antibodies if the nearest center-to-center 
distance between blobs (nuclei or cell bodies) in two channels was less than 7 µm (half of the cell body size). Experiments on 
vertebrates conformed to all relevant governmental and institutional regulations and were approved by the Institutional Animal Care 
and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the California Institute of Technology.  
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Figure 3. AAV-PHP.S transduces neurons throughout the PNS. We used AAV-PHP.S to 
package single-stranded (ss) rAAV genomes that express fluorescent reporters from either 
neuron-specific (e.g., hSyn1 and TH) or ubiquitous promoters (e.g., CAG). Viruses were 
delivered via retro-orbital injection to 6-8 week old wild-type or Cre transgenic mice and 
transgene expression was evaluated 2-3 weeks later. (a) ssAAV-PHP.S:hSyn1-mNeonGreen 
and ssAAV-PHP.S:CAG-DIO-mRuby2 were co-injected into a TH-IRES-Cre mouse at 1 x 1012 
vg/virus. Native mNeonGreen and mRuby2 fluorescence were assessed 2 weeks later via wide-
field (left) or confocal fluorescence microscopy (right). Images are from the second to sixth 
thoracic (T2-T6) (left) and eighth cervical to second thoracic (C8-T2) (right) paravertebral 
ganglia, which provide sympathetic innervation to thoracic organs including the heart. Arrows 
denote mNeonGreen-positive nerve fibers. (b) ssAAV-PHP.S:CAG-DIO-eYFP was injected into 
a TRPV1-IRES-Cre mouse at 1 x 1012 vg; gene expression in a nodose ganglion was evaluated 
3 weeks later. (c) A mixture of 3 separate viruses (ssAAV-PHP.S:CAG-DIO-XFPs) were injected 
into a TRPV1-IRES-Cre mouse at 1 x 1012 vg/virus; gene expression in a dorsal root ganglion 
was evaluated 2 weeks later. XFPs were mTurquoise2, mNeonGreen, or mRuby2. (d) ssAAV-
PHP.S:rTH-GFP and ssAAV-PHP.S:hSyn1-tdTomato-f (farnesylated) were co-injected into a 
C57BL/6J mouse at 5 x 1011 vg/virus; gene expression in the duodenum was assessed 22 d 
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later. The image stack includes both the myenteric and submucosal plexus. Inset shows 
zoomed-in view of ganglia containing TH+ cell bodies; tdTomato-f labels both thick nerve 
bundles and individual fibers. Whole-mount tissues were optically cleared using either 
ScaleSQ25 (a (right), c, and d) or RIMS24 (b) and imaged using confocal microscopy, unless 
stated otherwise; all confocal images are presented as maximum intensity projections. Refer to 
Table 1 for details regarding rAAV genomes. Experiments on vertebrates conformed to all 
relevant governmental and institutional regulations and were approved by the Institutional 
Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the 
California Institute of Technology.   
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Figure 4. AAV-PHP.S for mapping the anatomy and physiology of the heart. AAV-PHP.S 
viruses were delivered via retro-orbital injection to 6-8 week old wild-type or Cre transgenic 
mice. (a) AAV-PHP.S transduces the heart more efficiently than the current standard, AAV9. 
ssAAV9:CAG-NLS-GFP or ssAAV-PHP.S:CAG-NLS-GFP were injected into C57BL/6J mice at 
1 x 1012 vg. Native GFP fluorescence was assessed in whole mount hearts 4 weeks later via 
wide-field fluorescence microscopy (t7=8.449 and p<0.0001, unpaired t test). For AAV9 and 
AAV-PHP.S, n=5 and 4, respectively. (b) A mixture of 3 viruses (ssAAV-PHP.S:CAG-XFPs) 
were injected into a C57BL/6J mouse at 3.3 x 1011 vg/virus; gene expression in cardiac muscle 
was evaluated 11 d later, allowing individual cardiomyocytes to be easily distinguished from one 
another. XFPs were mTurquoise2, mNeonGreen, or mRuby2. (c) A mixture of 3 viruses 
(ssAAV-PHP.S:CAG-DIO-XFPs) were injected into a TRPV1-IRES-Cre mouse at 1 x 1012 
vg/virus; gene expression in TRPV1-expressing cardiac nerves was evaluated 2 weeks later. (d) 
ssAAV-PHP.S:Ef1ɑ-DIO-ChR2-eYFP was injected into a ChAT-IRES-Cre mouse at 1 x 1012 vg; 
gene expression in a cardiac ganglion was evaluated 3 weeks later (left). Ex vivo intracellular 
recordings were performed after 5 weeks of expression. DIC image (middle) shows the optical 
fiber for light delivery and electrode for concurrent intracellular recordings; inset shows a higher 
magnification image of a selected cell (asterisk). Cholinergic neurons generated action 
potentials in response to 473 nm light pulses (5 Hz, 20 ms) (right). Whole-mount tissues were 
optically cleared using ScaleSQ25 (b, c, and d (left)) and imaged using confocal microscopy, 
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unless stated otherwise; all confocal images are presented as maximum intensity projections. 
Refer to Table 1 for details regarding rAAV genomes. Experiments on vertebrates conformed to 
all relevant governmental and institutional regulations and were approved by the Institutional 
Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the 
California Institute of Technology.  
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Figure 5. A modular AAV toolbox for cell type-specific gene expression. The rAAV 
genome, contained in a pAAV plasmid (not shown), consists of an expression cassette flanked 
by two 145 bp inverted terminal repeats (ITRs); the entire genome, including the ITRs, cannot 
exceed 5 kb. The promoters, transgenes, localization signals, and recombination schemes are 
interchangeable. Gene regulatory elements, such as promoters and microRNA (miRNA) binding 
sites, determine the strength and specificity of transgene expression16. Transgenes may be 
constitutively expressed or flanked by recombination sites for flippase (Flp)- or Cre recombinase 
(Cre)-dependent expression. In the latter approach, the transgene remains in the double-floxed 
inverted orientation (DIO); Cre- or Flp-mediated inversion of the transgene enables cell type-
specific expression in transgenic mice (Fig. 3a-c and 4c-d). Localization sequences further 
restrict gene expression to distinct cellular compartments such as the nucleus (via one or more 
nuclear localization signals (NLS)) (Fig. 2), cytosol (via a nuclear exclusion signal (NES)58), or 
cell membrane (via farnesylation55, the CD4-259 transmembrane (TM) targeting domain, or 
PDZ60 protein-protein interaction domains) (Fig. 3d). Note that the 3’ UTR contains the 
woodchuck hepatitis posttranscriptional regulatory element (WPRE) (609 bp) and a 
polyadenylation signal (e.g., the human growth hormone (hGH) polyA) (479 bp) (not shown), 
both of which enhance transgene expression16. Use sequence editing and annotation software 
to determine the unique attributes of the rAAV genome. In Table 1, we list genomes used here 
and in our previous work2,3; see also Addgene’s plasmid repository for pAAVs that may be 
suitable for different applications. DREADDs = Designer Receptors Exclusively Activated by 
Designed Drugs; CRISPR = Clustered Regularly Interspaced Short Palindromic Repeats; 
shRNA = short hairpin RNA. 
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Figure 6. Timeline and AAV harvest procedure. (a) Timeline of the procedure. The entire protocol spans 8 d, excluding pause 
points on days 5 (Steps 11 and 14), 6 (Step 31), and 7 (Step 35) and the time required to evaluate transgene expression (Step 50). 
Days 1-7 (Steps 1-42) comprise the AAV production stage (Fig. 1). (b) Schematic of the AAV harvest procedure with images 
corresponding to indicated steps. Note that this iodixanol-based purification protocol does not eliminate empty capsids (i.e., capsids 
that fail to package a rAAV genome), as determined by negative staining transmission electron microscopy; empty particles are 
characterized by an electron-dense core. Grayed arrows and text denote steps where the supernatant and pellet can be bleached 
and discarded (Steps 13 and 18). 
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Figure 7. AAV purification procedure. (a-b) In Step 16, pipet the iodixanol density gradients 
(Video 1, 0:00-1:45). (a) Layer the 25% iodixanol underneath the 15% step (Video 1, 0:12-
1:28). (b) Add layers of increasing density under the previous layer (Video 1, 1:29-1:45); the 
gradients should have a sharp delineation between steps. (c) In Step 18, load the supernatant 
(Sup.) from Step 17 (Fig. 6b) above the 15% step (Video 1, 1:46-2:22). (d-e) In Step 19, fill 
each tube up to the neck with SAN digestion buffer and insert a black cap (d); place a spacer on 
top before weighing the tubes (e). (f) After ultracentrifugation (Step 22), secure the tube into the 
clamp setup above a container of 10% bleach (Step 24). Allow 10 ml of DPBS to drip through 
the syringe filter unit into a rinsed Amicon filter device (Step 25). (g) In Step 26, collect the virus 
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(Video 2, 0:00-1:30). Insert the needle approximately 4 mm below the 40/60% interface (i.e., 
where the tube just starts to curve) (Video 2, 0:06-0:21). Do not collect virus until the black cap 
is removed (asterisk) (Video 2, 0:22-0:30); do not collect from the protein layer at the 25/40% 
interface. (h) In Step 27, filter the virus/iodixanol (Video 2, 1:31-2:35). Inject the virus below the 
DPBS in the filter-attached syringe barrel (Video 2, 1:31-2:06) before pushing the virus/DPBS 
through the syringe filter unit and into the Amicon filter device. 
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 Vector name pAAV- Expression class Addgene ID 
Tu
na
bl
e 
ex
pr
es
si
on
 
TRE-mTurq2 
tTA-dependent 
99113 
TRE-eYFP 104056 
TRE-mRuby2 99114 
TRE-DIO-mTurq2 
Cre- and 
 tTA-dependent 
99115 
TRE-DIO-eYFP 104057 
TRE-DIO-tdTomato 99116 
TRE-DIO-mRuby2 99117 
CAG-tTA 
Inducer 
99118 
hSyn1-tTA 99119 
ihSyn1-tTA 99120 
ihSyn1-DIO-tTA 99121 
Ti
ss
ue
 w
id
e 
 e
xp
re
ss
io
n 
CAG-mTurq2 
Constitutive 
99122 
CAG-eYFP 104055 
CAG-mRuby2 99123 
CAG-NLS-GFP-NLS 104061 
CAG-DIO-mTurq2 
Cre-dependent 
104059 
CAG-DIO-eYFP 104052 
CAG-DIO-mRuby2 104058 
C
el
l t
yp
e-
sp
ec
ifi
c 
 
ex
pr
es
si
on
 
hSyn1-mTurq2 
Cell type-specific 
99125 
hSyn1-mRuby2 99126 
hSyn1-tdtomatoF 104060 
MBP-NLS-tdTomato 104054 
MsTH-GFP 99128 
GFAP-NLS-mTurq2 104053 
GFAP-mKate2.5f N/A 
mDlx-NLS-mRuby2 99130 
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AAV-PHP Capsid In vivo characteristics Production Addgene ID 
AAV-PHP.B Broad CNS transduction Good 103002 
AAV-PHP.B2 Broad CNS transduction Good 103003 
AAV-PHP.B3 Broad CNS transduction Good 103004 
AAV-PHP.eB Broad CNS transduction Good 103005 
AAV-PHP.S Broad PNS transduction Excellent 103006 
AAV-PHP.A Broad astrocyte transduction in CNS Poor N/A 
 
Table 1. AAV resources. A comprehensive list of plasmids used in this and related work2.3. The pHelper plasmid is available in 
Agilent's AAV helper-free kit (Agilent, cat. no. 240071). 
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Step 
 
Problem Potential reason Solution 
2 (transfection) Transfection solution 
is not cloudy 
DNA-PEI complexes have 
not formed 
Vortex the transfection solution and incubate at 
room temperature (RT) for 10 min before use; 
always use PEI at RT 
Transfection miscalculation Carefully follow the instructions in REAGENT 
SETUP and Supplementary Table 2 (sheet 
'Transfection calculator') to prepare the PEI + DPBS 
master mix and DNA + DPBS solutions 
3 (transfection) Low or no fluorescent 
protein expression 
post-transfection 
Low DNA purity Use an endotoxin-free plasmid purification kit to 
isolate plasmids; assess DNA purity (i.e., 260/280 
and 260/230 ratios) before transfection 
Mutations in plasmids Verify the integrity of pAAV plasmids by sequencing 
and restriction digest before transfection 
Poor cell health Maintain cells in an actively dividing state at 
recommended ratios (see REAGENT SETUP). Split 
cells at 1:2 no more than 24 h before transfection. 
Ensure cells are not over-confluent at the time of 
transfection, and change media no more than 24 h 
post-transfection 
Weak fluorescent reporter 
and/or promoter, or 
promoter cannot initiate 
gene expression in 
HEK293T cells 
Include a positive transfection control (e.g., pAAV-
CAG-EYFP, Addgene ID 104055). Note that some 
promoters may take 2-3 d to show expression 
Transgene expression 
depends on Flp or Cre 
recombinase 
Include a positive transfection control (see above) 
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Transfection miscalculation Carefully follow the instructions in REAGENT 
SETUP and Supplementary Table 2 (sheet 
'Transfection calculator') to prepare the PEI + DPBS 
master mix and DNA + DPBS solutions 
9 (AAV harvest) Cell lysate is not pink pH of lysate is too low Check the pH of the lysate by pipetting 30 µl onto a 
pH strip; adjust the pH to 8.5 with NaOH suitable for 
cell culture. In subsequent viral preps, ensure that 
the pH of SAN digestion buffer is 9.5-10.0; during 
cell lysis, the pH should drop to 8.5, which is optimal 
for SAN digestion 
Fluorescent protein 
expression from a strong 
promoter (e.g., CAG) 
Expression of blue/green or red fluorescent proteins 
from strong promoters can cause the lysate to turn 
yellow or red, respectively; proceed with AAV 
production 
16 (AAV 
purification) 
Air is expelled from 
the pipet while 
pouring the density 
gradients, causing the 
iodixanol steps to mix 
Too much iodixanol is 
released before removing 
the pipet from the OptiSeal 
tube 
Stop releasing the solution and slowly remove the 
pipet from the tube once the iodixanol is 
approximately 5 mm from the tip of the pipet (Video 
1, 0:42-0:58 and 1:20-1:25). If the gradients have no 
clear delineation between steps, repour the 
gradients 
Pipetting device does not 
have precise control 
Use a pipetting device with fine levels of control 
(see EQUIPMENT) 
Density gradients 
have no clear 
delineation between 
iodixanol steps 
Steps are mixed Repour the gradients (Video 1, 0:00-1:45); 
gradients should be poured fresh and not allowed to 
sit for too long  
26 (AAV 
purification) 
Cannot puncture 
OptiSeal tube with 
needle 
Not enough force is used Use a forward twisting motion to insert the needle 
into the tube (Video 2, 0:06-0:21); practice this step 
on an empty tube first 
Punctured two holes 
through OptiSeal tube 
Too much force is used See above. Do not remove the needle; carefully 
insert a new needle and proceed to collect virus 
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Cannot collect virus 
with needle 
Black cap is not removed Use the tube removal tool to remove the black cap 
from the tube after inserting the needle but before 
collecting virus (Fig. 7g and Video 2, 0:22-0:30) 
Plastic from the tube is 
lodged inside the needle 
Firmly replace the black cap and remove the needle 
from the tube; insert a new needle into the same 
hole, remove the black cap, and try collecting virus 
again 
Density gradient flows 
out of the needle hole 
in the tube after 
removing the needle 
Black cap is not firmly 
replaced 
Act quickly; use the beaker of bleach to catch the 
liquid and firmly replace the black cap to stop the 
flow. In subsequent viral preps, ensure that the 
black cap is replaced before removing the needle 
from the tube (Video 2, 1:19-1:30) 
31 (AAV 
purification) 
Unknown material is 
suspended in purified 
virus 
Salt or DNA precipitation Before titering or injecting the virus, spin down the 
precipitate at 3000 x g for 5 min at RT and transfer 
the supernatant (i.e., the virus) to a new screw-cap 
vial. We have not noticed a decrease in titer after 
removing precipitate from our preps; however, it is 
good practice to re-titer a virus if precipitate has 
formed 
Bacterial contamination Discard the virus. In subsequent viral preps, always 
sterile filter viruses after purification, and only open 
tubes containing viruses in a biosafety cabinet. 
During intravenous injections, never use the original 
virus stock; only bring an aliquot of what is needed 
for injection 
Carry-over from the filtration 
membrane of the Amicon 
filter device 
Sterile filter the virus 
42 (AAV titration) No SYBR signal 
detected for DNA 
Missing reagents (e.g., 
primers) in qPCR reaction 
Check that all qPCR reagents are added to the 
master mix and that DNA standards and virus 
samples are added to their respective wells 
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standards and virus 
samples 
Bad reagents Use fresh, properly stored qPCR reagents 
No SYBR signal 
detected for virus 
samples 
DNAse was not inactivated, 
resulting in degradation of 
the viral genome during 
proteinase K treatment 
Repeat the titration procedure; be sure to inactivate 
DNAse with EDTA at 70˚C (Step 34) 
Proteinase K was not 
inactivated, resulting in 
degradation of DNA 
polymerase during qPCR 
Repeat the titration prcoedure; be sure to inactivate 
Proteinase K at 95˚C (Step 37) 
Triplicates do not 
have similar Ct values 
Inaccurate pipetting and/or 
inadequate mixing of 
reagents 
Repeat the qPCR; pipet accurately and thoroughly 
mix all reagents before use 
Standard curve is not 
linear 
Inaccurate pipetting and/or 
inadequate mixing of 
reagents while preparing the 
DNA standard dilutions 
Repeat the qPCR; pipet accurately and thoroughly 
mix all reagents while preparing the DNA standard 
dilutions 
DNA standards degraded 
and/or stuck to the walls of 
1.5 ml tubes 
Prepare the DNA standard dilutions fresh, 
immediately prior to use; only use DNA/RNA LoBind 
microcentrifuge tubes 
Viral production 
efficiency is lower 
than expected 
(Supplementary 
Table 4, cell K27) 
Transfection, AAV harvest, 
AAV purification, and/or 
AAV titration were not 
successful 
Include a positive transfection/virus production 
control (e.g., pAAV-CAG-EYFP, Addgene ID 
104055) and a positive titration control. To 
determine at which stage virus is lost, collect a 30 µl 
sample from the cell lysate (Step 9), the media 
before PEG precipitation (Step 10), the PEG pellet 
resuspension (Step 14), and the lysate before (Step 
18) and after iodixanol purification (Step 26). 
AAV capsid and/or genome 
results in poor production 
efficiency 
Scale-up viral preps to ensure enough virus is 
produced for downstream applications 
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ITRs underwent 
recombination during 
bacterial growth 
After plasmid purification, but before transfection, 
digest pAAVs with SmaI to confirm the presence of 
ITRs, which are required for replication and 
encapsidation of the viral genome; always 
propagate pAAVs in recombination deficient 
bacterial strains  
43 (intravenous 
injection) 
A large volume (e.g., 
more than 100 µl, 
depending on the 
user) of virus needs 
to be injected 
Virus concentration is too 
low 
Reconcentrate the virus using an Amicon filter 
device; be sure to rinse the filtration membrane with 
DPBS prior to use (Step 25). After rinsing the 
membrane, add the virus and 15 ml of DPBS to the 
top chamber of the Amicon filter device; centrifuge 
at 3,000 x g at RT until the desired volume of 
solution remains in the top chamber 
48 (intravenous 
injection) 
  
Virus spills out of the 
eye during injection 
Incorrect needle placement Absorb the spilled virus using a paper towel; 
disinfect AAV-contaminated surfaces and materials 
with fresh 10% bleach or an equivalent disinfectant 
prior to disposal. Load the same insulin syringe with 
more virus, position the needle behind the globe of 
the eye in the retro-orbital sinus, and try the 
injection again. Practice injections using DPBS or 
saline until comfortable with the procedure 
Significant bleeding 
before, during, or 
after injection 
Incorrect needle placement Position the needle behind the globe of the eye in 
the retro-orbital sinus; never puncture the eye itself. 
Inject the virus slowly; following injection, carefully 
remove the needle at the same angle at which it 
was inserted. Practice injections using DPBS or 
saline until comfortable with the procedure 
Needle is left in the injection 
site for too long 
Once the needle is correctly placed in the eye, 
immediately inject the virus 
50 (evaluation of 
transgene 
expression) 
Weak or no 
transgene expression 
in tissue of interest 
Sufficient time has not 
passed for protein 
expression 
Wait longer for optimal protein expression 
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Dose is too low, or dose is 
too high, causing cell toxicity 
Inject multiple animals with a series of doses and 
sacrifice them at different time points (e.g., weekly) 
to determine the optimal dose 
Titer is inaccurate Re-titer viruses before injection if more than 1 
month has passed since titration; this will ensure 
that animals are administered the most accurate 
dose possible 
Virus degraded See above. Store AAV-PHP viruses at 4˚C and use 
them within 6 months, during which time we have 
not noticed a significant decrease in titers or 
transduction efficiency in vivo 
Weak or no expression from 
the AAV genome 
Verify the integrity of pAAV plasmids by sequencing 
and restriction digest before transfection. If possible, 
verify viral transduction and transgene expression in 
vitro before systemic administration 
 
Table 2. Troubleshooting AAV production, purification, and administration protocols. 
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